original_sentence	e1	e2	relation_type	metadata	preprocessed_sentence
Tamoxifen, an estrogen antagonist, is the standard hormone treatment for breast cancer. 	Tamoxifen	estrogen antagonist	none	{'e1': {'word': 'Tamoxifen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d209.s1.e0'}, 'e2': {'word': 'estrogen antagonist', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d209.s1.e1'}, 'sentence_id': 'DDI-MedLine.d209.s1'}	DRUG , an DRUGOTHER , is the standard hormone treatment for breast cancer .
Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. 	Paroxetine	fluoxetine	none	{'e1': {'word': 'Paroxetine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d209.s5.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d209.s5.e1'}, 'sentence_id': 'DDI-MedLine.d209.s5'}	DRUG and DRUGOTHER reduce the plasma concentration of DRUGUNRELATED by about 50 % .
Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. 	Paroxetine	endoxifen	mechanism	{'e1': {'word': 'Paroxetine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d209.s5.e0'}, 'e2': {'word': 'endoxifen', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d209.s5.e2'}, 'sentence_id': 'DDI-MedLine.d209.s5'}	DRUG and DRUGUNRELATED reduce the plasma concentration of DRUGOTHER by about 50 % .
Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. 	fluoxetine	endoxifen	mechanism	{'e1': {'word': 'fluoxetine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d209.s5.e1'}, 'e2': {'word': 'endoxifen', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d209.s5.e2'}, 'sentence_id': 'DDI-MedLine.d209.s5'}	DRUGUNRELATED and DRUG reduce the plasma concentration of DRUGOTHER by about 50 % .
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. 	tamoxifen	SSRI antidepressants	advise	{'e1': {'word': 'tamoxifen', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d209.s9.e0'}, 'e2': {'word': 'SSRI antidepressants', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d209.s9.e1'}, 'sentence_id': 'DDI-MedLine.d209.s9'}	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with DRUG for breast cancer , especially DRUGOTHER such as DRUGUNRELATED and DRUGUNRELATED .
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. 	tamoxifen	paroxetine	advise	{'e1': {'word': 'tamoxifen', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d209.s9.e0'}, 'e2': {'word': 'paroxetine', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d209.s9.e2'}, 'sentence_id': 'DDI-MedLine.d209.s9'}	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with DRUG for breast cancer , especially DRUGUNRELATED such as DRUGOTHER and DRUGUNRELATED .
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. 	tamoxifen	fluoxetine	advise	{'e1': {'word': 'tamoxifen', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d209.s9.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d209.s9.e3'}, 'sentence_id': 'DDI-MedLine.d209.s9'}	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with DRUG for breast cancer , especially DRUGUNRELATED such as DRUGUNRELATED and DRUGOTHER .
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. 	SSRI antidepressants	paroxetine	none	{'e1': {'word': 'SSRI antidepressants', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d209.s9.e1'}, 'e2': {'word': 'paroxetine', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d209.s9.e2'}, 'sentence_id': 'DDI-MedLine.d209.s9'}	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with DRUGUNRELATED for breast cancer , especially DRUG such as DRUGOTHER and DRUGUNRELATED .
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. 	SSRI antidepressants	fluoxetine	none	{'e1': {'word': 'SSRI antidepressants', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d209.s9.e1'}, 'e2': {'word': 'fluoxetine', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d209.s9.e3'}, 'sentence_id': 'DDI-MedLine.d209.s9'}	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with DRUGUNRELATED for breast cancer , especially DRUG such as DRUGUNRELATED and DRUGOTHER .
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. 	paroxetine	fluoxetine	none	{'e1': {'word': 'paroxetine', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d209.s9.e2'}, 'e2': {'word': 'fluoxetine', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d209.s9.e3'}, 'sentence_id': 'DDI-MedLine.d209.s9'}	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with DRUGUNRELATED for breast cancer , especially DRUGUNRELATED such as DRUG and DRUGOTHER .
Depression does not always require antidepressant drug therapy, and antidepressants have no proven preventive impact on hot flushes linked to the menopause. 	antidepressant drug	antidepressants	none	{'e1': {'word': 'antidepressant drug', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d209.s10.e0'}, 'e2': {'word': 'antidepressants', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d209.s10.e1'}, 'sentence_id': 'DDI-MedLine.d209.s10'}	Depression does not always require DRUG therapy , and DRUGOTHER have no proven preventive impact on hot flushes linked to the menopause .
If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.	antidepressant	tamoxifen	advise	{'e1': {'word': 'antidepressant', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d209.s11.e0'}, 'e2': {'word': 'tamoxifen', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d209.s11.e1'}, 'sentence_id': 'DDI-MedLine.d209.s11'}	If in certain cases , an DRUG is considered necessary , it may be advisable to replace DRUGOTHER with DRUGUNRELATED .
If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.	antidepressant	anastrozole	none	{'e1': {'word': 'antidepressant', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d209.s11.e0'}, 'e2': {'word': 'anastrozole', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d209.s11.e2'}, 'sentence_id': 'DDI-MedLine.d209.s11'}	If in certain cases , an DRUG is considered necessary , it may be advisable to replace DRUGUNRELATED with DRUGOTHER .
If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.	tamoxifen	anastrozole	none	{'e1': {'word': 'tamoxifen', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d209.s11.e1'}, 'e2': {'word': 'anastrozole', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d209.s11.e2'}, 'sentence_id': 'DDI-MedLine.d209.s11'}	If in certain cases , an DRUGUNRELATED is considered necessary , it may be advisable to replace DRUG with DRUGOTHER .
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)	Ticagrelor	Brilinta	none	{'e1': {'word': 'Ticagrelor', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d193.s0.e0'}, 'e2': {'word': 'Brilinta', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d193.s0.e1'}, 'sentence_id': 'DDI-MedLine.d193.s0'}	DRUG ( DRUGOTHER ) -- better than DRUGUNRELATED ( DRUGUNRELATED )
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)	Ticagrelor	clopidogrel	none	{'e1': {'word': 'Ticagrelor', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d193.s0.e0'}, 'e2': {'word': 'clopidogrel', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d193.s0.e2'}, 'sentence_id': 'DDI-MedLine.d193.s0'}	DRUG ( DRUGUNRELATED ) -- better than DRUGOTHER ( DRUGUNRELATED )
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)	Ticagrelor	Plavix	none	{'e1': {'word': 'Ticagrelor', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d193.s0.e0'}, 'e2': {'word': 'Plavix', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d193.s0.e3'}, 'sentence_id': 'DDI-MedLine.d193.s0'}	DRUG ( DRUGUNRELATED ) -- better than DRUGUNRELATED ( DRUGOTHER )
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)	Brilinta	clopidogrel	none	{'e1': {'word': 'Brilinta', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d193.s0.e1'}, 'e2': {'word': 'clopidogrel', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d193.s0.e2'}, 'sentence_id': 'DDI-MedLine.d193.s0'}	DRUGUNRELATED ( DRUG ) -- better than DRUGOTHER ( DRUGUNRELATED )
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)	Brilinta	Plavix	none	{'e1': {'word': 'Brilinta', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d193.s0.e1'}, 'e2': {'word': 'Plavix', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d193.s0.e3'}, 'sentence_id': 'DDI-MedLine.d193.s0'}	DRUGUNRELATED ( DRUG ) --better than DRUGUNRELATED ( DRUGOTHER )
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)	clopidogrel	Plavix	none	{'e1': {'word': 'clopidogrel', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d193.s0.e2'}, 'e2': {'word': 'Plavix', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d193.s0.e3'}, 'sentence_id': 'DDI-MedLine.d193.s0'}	DRUGUNRELATED ( DRUGUNRELATED ) -- better than DRUG ( DRUGOTHER )
The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). 	ticagrelor	Brilinta	none	{'e1': {'word': 'ticagrelor', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d193.s1.e0'}, 'e2': {'word': 'Brilinta', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d193.s1.e1'}, 'sentence_id': 'DDI-MedLine.d193.s1'}	The FDA has approved DRUG ( DRUGOTHER - AstraZeneca ) , an oral DRUGUNRELATED , for use with low - dose DRUGUNRELATED to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome ( ACS ) .
The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). 	ticagrelor	antiplatelet drug	none	{'e1': {'word': 'ticagrelor', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d193.s1.e0'}, 'e2': {'word': 'antiplatelet drug', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d193.s1.e2'}, 'sentence_id': 'DDI-MedLine.d193.s1'}	The FDA has approved DRUG ( DRUGUNRELATED - AstraZeneca ) , an oral DRUGOTHER , for use with low - dose DRUGUNRELATED to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome ( ACS ) .
The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). 	ticagrelor	aspirin	effect	{'e1': {'word': 'ticagrelor', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d193.s1.e0'}, 'e2': {'word': 'aspirin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d193.s1.e3'}, 'sentence_id': 'DDI-MedLine.d193.s1'}	The FDA has approved DRUG ( DRUGUNRELATED - AstraZeneca ) , an oral DRUGUNRELATED , for use with low - dose DRUGOTHER to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome ( ACS ) .
The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). 	Brilinta	antiplatelet drug	none	{'e1': {'word': 'Brilinta', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d193.s1.e1'}, 'e2': {'word': 'antiplatelet drug', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d193.s1.e2'}, 'sentence_id': 'DDI-MedLine.d193.s1'}	The FDA has approved DRUGUNRELATED ( DRUG - AstraZeneca ) , an oral DRUGOTHER , for use with low - dose DRUGUNRELATED to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome ( ACS ) .
The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). 	Brilinta	aspirin	effect	{'e1': {'word': 'Brilinta', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d193.s1.e1'}, 'e2': {'word': 'aspirin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d193.s1.e3'}, 'sentence_id': 'DDI-MedLine.d193.s1'}	The FDA has approved DRUGUNRELATED ( DRUG - AstraZeneca ) , an oral DRUGUNRELATED , for use with low - dose DRUGOTHER to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome ( ACS ) .
The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). 	antiplatelet drug	aspirin	none	{'e1': {'word': 'antiplatelet drug', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d193.s1.e2'}, 'e2': {'word': 'aspirin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d193.s1.e3'}, 'sentence_id': 'DDI-MedLine.d193.s1'}	The FDA has approved DRUGUNRELATED ( DRUGUNRELATED - AstraZeneca ) , an oral DRUG , for use with low - dose DRUGOTHER to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome ( ACS ) .
It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. 	clopidogrel	Plavix	none	{'e1': {'word': 'clopidogrel', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d193.s2.e0'}, 'e2': {'word': 'Plavix', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d193.s2.e1'}, 'sentence_id': 'DDI-MedLine.d193.s2'}	It will compete with DRUG ( DRUGOTHER ) and DRUGUNRELATED ( DRUGUNRELATED ) for such use .
It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. 	clopidogrel	prasugrel	none	{'e1': {'word': 'clopidogrel', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d193.s2.e0'}, 'e2': {'word': 'prasugrel', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d193.s2.e2'}, 'sentence_id': 'DDI-MedLine.d193.s2'}	It will compete with DRUG ( DRUGUNRELATED ) and DRUGOTHER ( DRUGUNRELATED ) for such use .
It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. 	clopidogrel	Effient	none	{'e1': {'word': 'clopidogrel', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d193.s2.e0'}, 'e2': {'word': 'Effient', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d193.s2.e3'}, 'sentence_id': 'DDI-MedLine.d193.s2'}	It will compete with DRUG ( DRUGUNRELATED ) and DRUGUNRELATED ( DRUGOTHER ) for such use .
It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. 	Plavix	prasugrel	none	{'e1': {'word': 'Plavix', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d193.s2.e1'}, 'e2': {'word': 'prasugrel', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d193.s2.e2'}, 'sentence_id': 'DDI-MedLine.d193.s2'}	It will compete with DRUGUNRELATED ( DRUG ) and DRUGOTHER ( DRUGUNRELATED ) for such use .
It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. 	Plavix	Effient	none	{'e1': {'word': 'Plavix', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d193.s2.e1'}, 'e2': {'word': 'Effient', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d193.s2.e3'}, 'sentence_id': 'DDI-MedLine.d193.s2'}	It will compete with DRUGUNRELATED ( DRUG ) and DRUGUNRELATED ( DRUGOTHER ) for such use .
It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. 	prasugrel	Effient	none	{'e1': {'word': 'prasugrel', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d193.s2.e2'}, 'e2': {'word': 'Effient', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d193.s2.e3'}, 'sentence_id': 'DDI-MedLine.d193.s2'}	It will compete with DRUGUNRELATED ( DRUGUNRELATED ) and DRUG ( DRUGOTHER ) for such use .
"Influence of piperine on ibuprofen induced antinociception and its pharmacokinetics.
"	piperine	ibuprofen	none	{'e1': {'word': 'piperine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d195.s0.e0'}, 'e2': {'word': 'ibuprofen', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d195.s0.e1'}, 'sentence_id': 'DDI-MedLine.d195.s0'}	Influence of DRUG on DRUGOTHER induced antinociception and its pharmacokinetics .
In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. 	piperine	ibuprofen	effect	{'e1': {'word': 'piperine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d195.s4.e0'}, 'e2': {'word': 'ibuprofen', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d195.s4.e1'}, 'sentence_id': 'DDI-MedLine.d195.s4'}	In the present study DRUG ( 10 mg / kg ) significantly increased the dose - dependent antinociceptive activity of DRUGOTHER evaluated by both DRUGUNRELATED writhing and formalin test , when it was administered with DRUGUNRELATED .
In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. 	piperine	acetic acid	none	{'e1': {'word': 'piperine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d195.s4.e0'}, 'e2': {'word': 'acetic acid', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d195.s4.e2'}, 'sentence_id': 'DDI-MedLine.d195.s4'}	In the present study DRUG ( 10 mg / kg ) significantly increased the dose - dependent antinociceptive activity of DRUGUNRELATED evaluated by both DRUGOTHER writhing and formalin test , when it was administered with DRUGUNRELATED .
In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. 	piperine	ibuprofen	none	{'e1': {'word': 'piperine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d195.s4.e0'}, 'e2': {'word': 'ibuprofen', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d195.s4.e3'}, 'sentence_id': 'DDI-MedLine.d195.s4'}	In the present study DRUG ( 10 mg / kg ) significantly increased the dose - dependent antinociceptive activity of DRUGUNRELATED evaluated by both DRUGUNRELATED writhing and formalin test , when it was administered with DRUGOTHER .
In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. 	ibuprofen	acetic acid	none	{'e1': {'word': 'ibuprofen', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d195.s4.e1'}, 'e2': {'word': 'acetic acid', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d195.s4.e2'}, 'sentence_id': 'DDI-MedLine.d195.s4'}	In the present study DRUGUNRELATED ( 10 mg / kg ) significantly increased the dose - dependent antinociceptive activity of DRUG evaluated by both DRUGOTHER writhing and formalin test , when it was administered with DRUGUNRELATED .
In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. 	ibuprofen	ibuprofen	none	{'e1': {'word': 'ibuprofen', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d195.s4.e1'}, 'e2': {'word': 'ibuprofen', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d195.s4.e3'}, 'sentence_id': 'DDI-MedLine.d195.s4'}	In the present study DRUGUNRELATED ( 10 mg / kg ) significantly increased the dose - dependent antinociceptive activity of DRUG evaluated by both DRUGUNRELATED writhing and formalin test , when it was administered with DRUGOTHER .
In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. 	acetic acid	ibuprofen	none	{'e1': {'word': 'acetic acid', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d195.s4.e2'}, 'e2': {'word': 'ibuprofen', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d195.s4.e3'}, 'sentence_id': 'DDI-MedLine.d195.s4'}	In the present study DRUGUNRELATED ( 10 mg / kg ) significantly increased the dose - dependent antinociceptive activity of DRUGUNRELATED evaluated by both DRUG writhing and formalin test , when it was administered with DRUGOTHER .
Ibuprofen plasma concentration was also increased when it was administered with piperine. 	Ibuprofen	piperine	mechanism	{'e1': {'word': 'Ibuprofen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d195.s5.e0'}, 'e2': {'word': 'piperine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d195.s5.e1'}, 'sentence_id': 'DDI-MedLine.d195.s5'}	DRUG plasma concentration was also increased when it was administered with DRUGOTHER .
The synergistic antinociception activity of ibuprofen when administered with piperine can be attributed to increased plasma concentration of ibuprofen. 	ibuprofen	piperine	mechanism	{'e1': {'word': 'ibuprofen', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d195.s6.e0'}, 'e2': {'word': 'piperine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d195.s6.e1'}, 'sentence_id': 'DDI-MedLine.d195.s6'}	The synergistic antinociception activity of DRUG when administered with DRUGOTHER can be attributed to increased plasma concentration of DRUGUNRELATED .
The synergistic antinociception activity of ibuprofen when administered with piperine can be attributed to increased plasma concentration of ibuprofen. 	ibuprofen	ibuprofen	none	{'e1': {'word': 'ibuprofen', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d195.s6.e0'}, 'e2': {'word': 'ibuprofen', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d195.s6.e2'}, 'sentence_id': 'DDI-MedLine.d195.s6'}	The synergistic antinociception activity of DRUG when administered with DRUGUNRELATED can be attributed to increased plasma concentration of DRUGOTHER .
The synergistic antinociception activity of ibuprofen when administered with piperine can be attributed to increased plasma concentration of ibuprofen. 	piperine	ibuprofen	none	{'e1': {'word': 'piperine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d195.s6.e1'}, 'e2': {'word': 'ibuprofen', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d195.s6.e2'}, 'sentence_id': 'DDI-MedLine.d195.s6'}	The synergistic antinociception activity of DRUGUNRELATED when administered with DRUG can be attributed to increased plasma concentration of DRUGOTHER .
From this study it can be concluded that piperine can be used as a bioenhancer along with ibuprofen.	piperine	ibuprofen	effect	{'e1': {'word': 'piperine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d195.s7.e0'}, 'e2': {'word': 'ibuprofen', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d195.s7.e1'}, 'sentence_id': 'DDI-MedLine.d195.s7'}	From this study it can be concluded that DRUG can be used as a bioenhancer along with DRUGOTHER .
"Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study.
"	Antidepressant	warfarin	none	{'e1': {'word': 'Antidepressant', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s0.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d218.s0.e1'}, 'sentence_id': 'DDI-MedLine.d218.s0'}	DRUG - DRUGOTHER interaction and associated gastrointestinal bleeding risk in a case - control study .
We sought to evaluate whether initiation of an antidepressant increases the risk of hospitalization for gastrointestinal bleeding in warfarin users.	antidepressant	warfarin	none	{'e1': {'word': 'antidepressant', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d218.s3.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d218.s3.e1'}, 'sentence_id': 'DDI-MedLine.d218.s3'}	We sought to evaluate whether initiation of an DRUG increases the risk of hospitalization for gastrointestinal bleeding in DRUGOTHER users .
In total, 430,455 warfarin users contributed 407,370 person-years of warfarin use. 	warfarin	warfarin	none	{'e1': {'word': 'warfarin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d218.s5.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d218.s5.e1'}, 'sentence_id': 'DDI-MedLine.d218.s5'}	In total , 430,455 DRUG users contributed 407,370 person - years of DRUGOTHER use .
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	Warfarin	citalopram	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s8.e0'}, 'e2': {'word': 'citalopram', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d218.s8.e1'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	DRUG users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUGOTHER ( OR = 1.73 [ 95 % CI , 1.25 - 2.38 ] ) , DRUGUNRELATED ( OR = 1.63 [ 95 % CI , 1.11 - 2.38 ] ) , DRUGUNRELATED ( OR = 1.64 [ 95 % CI , 1.27 - 2.12 ] ) , DRUGUNRELATED ( OR = 1.47 [ 95 % CI , 1.02 - 2.11 ] ) .
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	Warfarin	fluoxetine	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s8.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d218.s8.e2'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	DRUG users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUGUNRELATED ( OR = 1.73 [ 95 % CI , 1.25 - 2.38 ] ) , DRUGOTHER ( OR = 1.63 [ 95 % CI , 1.11 - 2.38 ] ) , DRUGUNRELATED ( OR = 1.64 [ 95 % CI , 1.27 - 2.12 ] ) , DRUGUNRELATED ( OR = 1.47 [ 95 % CI , 1.02 - 2.11 ] ) .
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	Warfarin	paroxetine	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s8.e0'}, 'e2': {'word': 'paroxetine', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d218.s8.e3'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	DRUG users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUGUNRELATED ( OR = 1.73 [ 95 % CI , 1.25 - 2.38 ] ) , DRUGUNRELATED ( OR = 1.63 [ 95 % CI , 1.11 - 2.38 ] ) , DRUGOTHER ( OR = 1.64 [ 95 % CI , 1.27 - 2.12 ] ) , DRUGUNRELATED ( OR = 1.47 [ 95 % CI , 1.02 - 2.11 ] ) .
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	Warfarin	amitriptyline	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s8.e0'}, 'e2': {'word': 'amitriptyline', 'word_index': [(61, 61)], 'id': 'DDI-MedLine.d218.s8.e4'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	DRUG users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUGUNRELATED ( OR = 1.73 [ 95 % CI , 1.25 - 2.38 ] ) , DRUGUNRELATED ( OR = 1.63 [ 95 % CI , 1.11 - 2.38 ] ) , DRUGUNRELATED ( OR = 1.64 [ 95 % CI , 1.27 - 2.12 ] ) , DRUGOTHER ( OR = 1.47 [ 95 % CI , 1.02 - 2.11 ] ) .
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	citalopram	fluoxetine	none	{'e1': {'word': 'citalopram', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d218.s8.e1'}, 'e2': {'word': 'fluoxetine', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d218.s8.e2'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	DRUGUNRELATED users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUG ( OR = 1.73 [ 95 % CI , 1.25 - 2.38 ] ) , DRUGOTHER ( OR = 1.63 [ 95 % CI , 1.11 - 2.38 ] ) , DRUGUNRELATED ( OR = 1.64 [ 95 % CI , 1.27 - 2.12 ] ) , DRUGUNRELATED ( OR = 1.47 [ 95 % CI , 1.02 - 2.11 ] ) .
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	citalopram	paroxetine	none	{'e1': {'word': 'citalopram', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d218.s8.e1'}, 'e2': {'word': 'paroxetine', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d218.s8.e3'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	DRUGUNRELATED users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUG ( OR = 1.73 [ 95 % CI , 1.25 - 2.38 ] ) , DRUGUNRELATED ( OR = 1.63 [ 95 % CI , 1.11 - 2.38 ] ) , DRUGOTHER ( OR = 1.64 [ 95 % CI , 1.27 - 2.12 ] ) , DRUGUNRELATED ( OR = 1.47 [ 95 % CI , 1.02 - 2.11 ] ) .
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	citalopram	amitriptyline	none	{'e1': {'word': 'citalopram', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d218.s8.e1'}, 'e2': {'word': 'amitriptyline', 'word_index': [(61, 61)], 'id': 'DDI-MedLine.d218.s8.e4'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	DRUGUNRELATED users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUG ( OR = 1.73 [ 95 % CI , 1.25 - 2.38 ] ) , DRUGUNRELATED ( OR = 1.63 [ 95 % CI , 1.11 - 2.38 ] ) , DRUGUNRELATED ( OR = 1.64 [ 95 % CI , 1.27 - 2.12 ] ) , DRUGOTHER ( OR = 1.47 [ 95 % CI , 1.02 - 2.11 ] ) .
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	fluoxetine	paroxetine	none	{'e1': {'word': 'fluoxetine', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d218.s8.e2'}, 'e2': {'word': 'paroxetine', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d218.s8.e3'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	DRUGUNRELATED users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUGUNRELATED ( OR = 1.73 [ 95 % CI , 1.25 - 2.38 ] ) , DRUG ( OR = 1.63 [ 95 % CI , 1.11 - 2.38 ] ) , DRUGOTHER ( OR = 1.64 [ 95 % CI , 1.27 - 2.12 ] ) , DRUGUNRELATED ( OR = 1.47 [ 95 % CI , 1.02 - 2.11 ] ) .
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	fluoxetine	amitriptyline	none	{'e1': {'word': 'fluoxetine', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d218.s8.e2'}, 'e2': {'word': 'amitriptyline', 'word_index': [(61, 61)], 'id': 'DDI-MedLine.d218.s8.e4'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	DRUGUNRELATED users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUGUNRELATED ( OR = 1.73 [ 95 % CI , 1.25 - 2.38 ] ) , DRUG ( OR = 1.63 [ 95 % CI , 1.11 - 2.38 ] ) , DRUGUNRELATED ( OR = 1.64 [ 95 % CI , 1.27 - 2.12 ] ) , DRUGOTHER ( OR = 1.47 [ 95 % CI , 1.02 - 2.11 ] ) .
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	paroxetine	amitriptyline	none	{'e1': {'word': 'paroxetine', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d218.s8.e3'}, 'e2': {'word': 'amitriptyline', 'word_index': [(61, 61)], 'id': 'DDI-MedLine.d218.s8.e4'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	DRUGUNRELATED users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUGUNRELATED ( OR = 1.73 [ 95 % CI , 1.25 - 2.38 ] ) , DRUGUNRELATED ( OR = 1.63 [ 95 % CI , 1.11 - 2.38 ] ) , DRUG ( OR = 1.64 [ 95 % CI , 1.27 - 2.12 ] ) , DRUGOTHER ( OR = 1.47 [ 95 % CI , 1.02 - 2.11 ] ) .
Also mirtazapine, which is not believed to interact with warfarin, increased the risk of GI bleeding (OR   =   1.75 [95% CI, 1.30-2.35]). 	mirtazapine	warfarin	effect	{'e1': {'word': 'mirtazapine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d218.s9.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d218.s9.e1'}, 'sentence_id': 'DDI-MedLine.d218.s9'}	Also DRUG , which is not believed to interact with DRUGOTHER , increased the risk of GI bleeding ( OR = 1.75 [ 95 % CI , 1.30 - 2.35 ] ) .
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	Warfarin	citalopram	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s10.e0'}, 'e2': {'word': 'citalopram', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d218.s10.e1'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	DRUG users who initiated DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , or DRUGUNRELATED had an increased risk of hospitalization for gastrointestinal bleeding .
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	Warfarin	fluoxetine	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s10.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d218.s10.e2'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	DRUG users who initiated DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , or DRUGUNRELATED had an increased risk of hospitalization for gastrointestinal bleeding .
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	Warfarin	paroxetine	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s10.e0'}, 'e2': {'word': 'paroxetine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d218.s10.e3'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	DRUG users who initiated DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , or DRUGUNRELATED had an increased risk of hospitalization for gastrointestinal bleeding .
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	Warfarin	amitriptyline	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s10.e0'}, 'e2': {'word': 'amitriptyline', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d218.s10.e4'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	DRUG users who initiated DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , or DRUGUNRELATED had an increased risk of hospitalization for gastrointestinal bleeding .
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	Warfarin	mirtazapine	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s10.e0'}, 'e2': {'word': 'mirtazapine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d218.s10.e5'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	DRUG users who initiated DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , or DRUGOTHER had an increased risk of hospitalization for gastrointestinal bleeding .
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	citalopram	fluoxetine	none	{'e1': {'word': 'citalopram', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d218.s10.e1'}, 'e2': {'word': 'fluoxetine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d218.s10.e2'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	DRUGUNRELATED users who initiated DRUG , DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , or DRUGUNRELATED had an increased risk of hospitalization for gastrointestinal bleeding .
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	citalopram	paroxetine	none	{'e1': {'word': 'citalopram', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d218.s10.e1'}, 'e2': {'word': 'paroxetine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d218.s10.e3'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	DRUGUNRELATED users who initiated DRUG , DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , or DRUGUNRELATED had an increased risk of hospitalization for gastrointestinal bleeding .
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	citalopram	amitriptyline	none	{'e1': {'word': 'citalopram', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d218.s10.e1'}, 'e2': {'word': 'amitriptyline', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d218.s10.e4'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	DRUGUNRELATED users who initiated DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , or DRUGUNRELATED had an increased risk of hospitalization for gastrointestinal bleeding .
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	citalopram	mirtazapine	none	{'e1': {'word': 'citalopram', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d218.s10.e1'}, 'e2': {'word': 'mirtazapine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d218.s10.e5'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	DRUGUNRELATED users who initiated DRUG , DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , or DRUGOTHER had an increased risk of hospitalization for gastrointestinal bleeding .
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	fluoxetine	paroxetine	none	{'e1': {'word': 'fluoxetine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d218.s10.e2'}, 'e2': {'word': 'paroxetine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d218.s10.e3'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	DRUGUNRELATED users who initiated DRUGUNRELATED , DRUG , DRUGOTHER , DRUGUNRELATED , or DRUGUNRELATED had an increased risk of hospitalization for gastrointestinal bleeding .
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	fluoxetine	amitriptyline	none	{'e1': {'word': 'fluoxetine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d218.s10.e2'}, 'e2': {'word': 'amitriptyline', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d218.s10.e4'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	DRUGUNRELATED users who initiated DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGOTHER , or DRUGUNRELATED had an increased risk of hospitalization for gastrointestinal bleeding .
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	fluoxetine	mirtazapine	none	{'e1': {'word': 'fluoxetine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d218.s10.e2'}, 'e2': {'word': 'mirtazapine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d218.s10.e5'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	DRUGUNRELATED users who initiated DRUGUNRELATED , DRUG , DRUGUNRELATED , DRUGUNRELATED , or DRUGOTHER had an increased risk of hospitalization for gastrointestinal bleeding .
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	paroxetine	amitriptyline	none	{'e1': {'word': 'paroxetine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d218.s10.e3'}, 'e2': {'word': 'amitriptyline', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d218.s10.e4'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	DRUGUNRELATED users who initiated DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGOTHER , or DRUGUNRELATED had an increased risk of hospitalization for gastrointestinal bleeding .
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	paroxetine	mirtazapine	none	{'e1': {'word': 'paroxetine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d218.s10.e3'}, 'e2': {'word': 'mirtazapine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d218.s10.e5'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	DRUGUNRELATED users who initiated DRUGUNRELATED , DRUGUNRELATED , DRUG , DRUGUNRELATED , or DRUGOTHER had an increased risk of hospitalization for gastrointestinal bleeding .
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	amitriptyline	mirtazapine	none	{'e1': {'word': 'amitriptyline', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d218.s10.e4'}, 'e2': {'word': 'mirtazapine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d218.s10.e5'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	DRUGUNRELATED users who initiated DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , DRUG , or DRUGOTHER had an increased risk of hospitalization for gastrointestinal bleeding .
"Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease.
"	cinacalcet	darbepoetin	none	{'e1': {'word': 'cinacalcet', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d166.s0.e0'}, 'e2': {'word': 'darbepoetin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d166.s0.e1'}, 'sentence_id': 'DDI-MedLine.d166.s0'}	Improved parathyroid hormone control by DRUG is associated with reduction in DRUGOTHER requirement in patients with end-stage renal disease .
Uncontrolled hy-per-parathyroidism causes bone marrow fibrosis, leading to erythropoietin (EPO) resistance. 	erythropoietin	EPO	none	{'e1': {'word': 'erythropoietin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d166.s1.e0'}, 'e2': {'word': 'EPO', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d166.s1.e1'}, 'sentence_id': 'DDI-MedLine.d166.s1'}	Uncontrolled hy - per-parathyroidism causes bone marrow fibrosis , leading to DRUG ( DRUGOTHER ) resistance .
Medical treatment with cinacalcet is effective in reducing plasma parathyroid hormone (PTH) levels, but its effect on darbepoetin dosing is unknown. 	cinacalcet	darbepoetin	none	{'e1': {'word': 'cinacalcet', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d166.s2.e0'}, 'e2': {'word': 'darbepoetin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d166.s2.e1'}, 'sentence_id': 'DDI-MedLine.d166.s2'}	Medical treatment with DRUG is effective in reducing plasma parathyroid hormone ( PTH ) levels , but its effect on DRUGOTHER dosing is unknown .
The primary objective of the study was to ascertain the difference in darbepoetin responsiveness before and after 12 months of cinacalcet therapy. 	darbepoetin	cinacalcet	none	{'e1': {'word': 'darbepoetin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d166.s6.e0'}, 'e2': {'word': 'cinacalcet', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d166.s6.e1'}, 'sentence_id': 'DDI-MedLine.d166.s6'}	The primary objective of the study was to ascertain the difference in DRUG responsiveness before and after 12 months of DRUGOTHER therapy .
Reduction of PTH by cinacalcet is associated with a decrease in darbepoetin requirement. 	cinacalcet	darbepoetin	effect	{'e1': {'word': 'cinacalcet', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d166.s17.e0'}, 'e2': {'word': 'darbepoetin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d166.s17.e1'}, 'sentence_id': 'DDI-MedLine.d166.s17'}	Reduction of PTH by DRUG is associated with a decrease in DRUGOTHER requirement .
Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.	sunitinib	docetaxel	int	{'e1': {'word': 'sunitinib', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d179.s0.e0'}, 'e2': {'word': 'docetaxel', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d179.s0.e1'}, 'sentence_id': 'DDI-MedLine.d179.s0'}	Synergistic interaction between DRUG and DRUGOTHER is sequence dependent in human non-small lung cancer with EGFR TKIs - resistant mutation .
This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.	sunitinib	sunitinib	none	{'e1': {'word': 'sunitinib', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d179.s2.e0'}, 'e2': {'word': 'sunitinib', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d179.s2.e1'}, 'sentence_id': 'DDI-MedLine.d179.s2'}	This study was aimed to investigate the efficacy of single use of DRUG and that of concurrent or sequential administration of DRUGOTHER and DRUGUNRELATED in NSCLC cell lines that are resistant to EGFR TKIs .
This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.	sunitinib	docetaxel	none	{'e1': {'word': 'sunitinib', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d179.s2.e0'}, 'e2': {'word': 'docetaxel', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d179.s2.e2'}, 'sentence_id': 'DDI-MedLine.d179.s2'}	This study was aimed to investigate the efficacy of single use of DRUG and that of concurrent or sequential administration of DRUGUNRELATED and DRUGOTHER in NSCLC cell lines that are resistant to EGFR TKIs .
This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.	sunitinib	docetaxel	none	{'e1': {'word': 'sunitinib', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d179.s2.e1'}, 'e2': {'word': 'docetaxel', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d179.s2.e2'}, 'sentence_id': 'DDI-MedLine.d179.s2'}	This study was aimed to investigate the efficacy of single use of DRUGUNRELATED and that of concurrent or sequential administration of DRUG and DRUGOTHER in NSCLC cell lines that are resistant to EGFR TKIs .
NSCLC cell lines with EGFR T790M mutation and K-ras mutation were exposed to either sunitinib or docetaxel or both based on various sequential administrations. 	sunitinib	docetaxel	none	{'e1': {'word': 'sunitinib', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d179.s3.e0'}, 'e2': {'word': 'docetaxel', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d179.s3.e1'}, 'sentence_id': 'DDI-MedLine.d179.s3'}	NSCLC cell lines with EGFR T790M mutation and K - ras mutation were exposed to either DRUG or DRUGOTHER or both based on various sequential administrations .
Sunitinib exhibited dose-dependent growth inhibition in NSCLC cell lines and arrested cell cycle at G1 phase, whereas docetaxel arrested at S phase. 	Sunitinib	docetaxel	none	{'e1': {'word': 'Sunitinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d179.s5.e0'}, 'e2': {'word': 'docetaxel', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d179.s5.e1'}, 'sentence_id': 'DDI-MedLine.d179.s5'}	DRUG exhibited dose - dependent growth inhibition in NSCLC cell lines and arrested cell cycle at G1 phase , whereas DRUGOTHER arrested at S phase .
Although single or concurrent use of sunitinib and docetaxel has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity. 	sunitinib	docetaxel	effect	{'e1': {'word': 'sunitinib', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d179.s6.e0'}, 'e2': {'word': 'docetaxel', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d179.s6.e1'}, 'sentence_id': 'DDI-MedLine.d179.s6'}	Although single or concurrent use of DRUG and DRUGOTHER has some anti-proliferative effects , the sequential administrations of both drugs remarkably enhanced anti-tumor activity .
When cells were exposed to docetaxel followed by sunitinib, synergism was observed. 	docetaxel	sunitinib	effect	{'e1': {'word': 'docetaxel', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d179.s7.e0'}, 'e2': {'word': 'sunitinib', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d179.s7.e1'}, 'sentence_id': 'DDI-MedLine.d179.s7'}	When cells were exposed to DRUG followed by DRUGOTHER , synergism was observed .
The molecular basis of this synergism is that the signaling pathways that were initially activated by docetaxel exposure were efficiently suppressed by the subsequent exposure to sunitinib. 	docetaxel	sunitinib	effect	{'e1': {'word': 'docetaxel', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d179.s8.e0'}, 'e2': {'word': 'sunitinib', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d179.s8.e1'}, 'sentence_id': 'DDI-MedLine.d179.s8'}	The molecular basis of this synergism is that the signaling pathways that were initially activated by DRUG exposure were efficiently suppressed by the subsequent exposure to DRUGOTHER .
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	Sunitinib	docetaxel	none	{'e1': {'word': 'Sunitinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d179.s10.e0'}, 'e2': {'word': 'docetaxel', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d179.s10.e1'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	DRUG as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K - ras mutations but the sequential administration of DRUGOTHER followed by DRUGUNRELATED is superior to DRUGUNRELATED followed by DRUGUNRELATED and concurrent administration .
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	Sunitinib	sunitinib	none	{'e1': {'word': 'Sunitinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d179.s10.e0'}, 'e2': {'word': 'sunitinib', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d179.s10.e2'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	DRUG as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K - ras mutations but the sequential administration of DRUGUNRELATED followed by DRUGOTHER is superior to DRUGUNRELATED followed by DRUGUNRELATED and concurrent administration .
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	Sunitinib	sunitinib	none	{'e1': {'word': 'Sunitinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d179.s10.e0'}, 'e2': {'word': 'sunitinib', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d179.s10.e3'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	DRUG as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K - ras mutations but the sequential administration of DRUGUNRELATED followed by DRUGUNRELATED is superior to DRUGOTHER followed by DRUGUNRELATED and concurrent administration .
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	Sunitinib	docetaxel	none	{'e1': {'word': 'Sunitinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d179.s10.e0'}, 'e2': {'word': 'docetaxel', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d179.s10.e4'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	DRUG as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K - ras mutations but the sequential administration of DRUGUNRELATED followed by DRUGUNRELATED is superior to DRUGUNRELATED followed by DRUGOTHER and concurrent administration .
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	docetaxel	sunitinib	effect	{'e1': {'word': 'docetaxel', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d179.s10.e1'}, 'e2': {'word': 'sunitinib', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d179.s10.e2'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	DRUGUNRELATED as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K - ras mutations but the sequential administration of DRUG followed by DRUGOTHER is superior to DRUGUNRELATED followed by DRUGUNRELATED and concurrent administration .
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	docetaxel	sunitinib	none	{'e1': {'word': 'docetaxel', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d179.s10.e1'}, 'e2': {'word': 'sunitinib', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d179.s10.e3'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	DRUGUNRELATED as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K - ras mutations but the sequential administration of DRUG followed by DRUGUNRELATED is superior to DRUGOTHER followed by DRUGUNRELATED and concurrent administration .
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	docetaxel	docetaxel	none	{'e1': {'word': 'docetaxel', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d179.s10.e1'}, 'e2': {'word': 'docetaxel', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d179.s10.e4'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	DRUGUNRELATED as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K - ras mutations but the sequential administration of DRUG followed by DRUGUNRELATED is superior to DRUGUNRELATED followed by DRUGOTHER and concurrent administration .
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	sunitinib	sunitinib	none	{'e1': {'word': 'sunitinib', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d179.s10.e2'}, 'e2': {'word': 'sunitinib', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d179.s10.e3'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	DRUGUNRELATED as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K - ras mutations but the sequential administration of DRUGUNRELATED followed by DRUG is superior to DRUGOTHER followed by DRUGUNRELATED and concurrent administration .
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	sunitinib	docetaxel	none	{'e1': {'word': 'sunitinib', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d179.s10.e2'}, 'e2': {'word': 'docetaxel', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d179.s10.e4'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	DRUGUNRELATED as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K - ras mutations but the sequential administration of DRUGUNRELATED followed by DRUG is superior to DRUGUNRELATED followed by DRUGOTHER and concurrent administration .
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	sunitinib	docetaxel	none	{'e1': {'word': 'sunitinib', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d179.s10.e3'}, 'e2': {'word': 'docetaxel', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d179.s10.e4'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	DRUGUNRELATED as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K - ras mutations but the sequential administration of DRUGUNRELATED followed by DRUGUNRELATED is superior to DRUG followed by DRUGOTHER and concurrent administration .
"[Interaction between clopidogrel and proton pump inhibitors].
"	clopidogrel	proton pump inhibitors	none	{'e1': {'word': 'clopidogrel', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d143.s0.e0'}, 'e2': {'word': 'proton pump inhibitors', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d143.s0.e1'}, 'sentence_id': 'DDI-MedLine.d143.s0'}	[ Interaction between DRUG and DRUGOTHER ] .
The drug interaction between proton pump inhibitors and clopidogrel has been the subject of much study in recent years. 	proton pump inhibitors	clopidogrel	none	{'e1': {'word': 'proton pump inhibitors', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d143.s1.e0'}, 'e2': {'word': 'clopidogrel', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d143.s1.e1'}, 'sentence_id': 'DDI-MedLine.d143.s1'}	The drug interaction between DRUG and DRUGOTHER has been the subject of much study in recent years .
Contradictory results regarding the effect of proton pump inhibitors on platelet reactivity and on clinical outcome in clopidogrel-treated patients have been reported in literature. 	proton pump inhibitors	clopidogrel	none	{'e1': {'word': 'proton pump inhibitors', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d143.s2.e0'}, 'e2': {'word': 'clopidogrel', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d143.s2.e1'}, 'sentence_id': 'DDI-MedLine.d143.s2'}	Contradictory results regarding the effect of DRUG on platelet reactivity and on clinical outcome in DRUGOTHER - treated patients have been reported in literature .
Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. 	omeprazole	clopidogrel	mechanism	{'e1': {'word': 'omeprazole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d143.s3.e0'}, 'e2': {'word': 'clopidogrel', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d143.s3.e1'}, 'sentence_id': 'DDI-MedLine.d143.s3'}	Concomitant use of DRUG and DRUGOTHER was found to decrease the exposure ( AUC ) to clopidogrel 's active metabolite by 50 % and to sharply increase platelet reactivity , as a result of inhibition by DRUGUNRELATED of CYP2C19 , a cytochrome P450 ( CYP ) enzyme .
Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. 	omeprazole	omeprazole	none	{'e1': {'word': 'omeprazole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d143.s3.e0'}, 'e2': {'word': 'omeprazole', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d143.s3.e2'}, 'sentence_id': 'DDI-MedLine.d143.s3'}	Concomitant use of DRUG and DRUGUNRELATED was found to decrease the exposure ( AUC ) to clopidogrel 's active metabolite by 50 % and to sharply increase platelet reactivity , as a result of inhibition by DRUGOTHER of CYP2C19 , a cytochrome P450 ( CYP ) enzyme .
Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. 	clopidogrel	omeprazole	none	{'e1': {'word': 'clopidogrel', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d143.s3.e1'}, 'e2': {'word': 'omeprazole', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d143.s3.e2'}, 'sentence_id': 'DDI-MedLine.d143.s3'}	Concomitant use of DRUGUNRELATED and DRUG was found to decrease the exposure ( AUC ) to clopidogrel 's active metabolite by 50 % and to sharply increase platelet reactivity , as a result of inhibition by DRUGOTHER of CYP2C19 , a cytochrome P450 ( CYP ) enzyme .
Pantoprazole has a much weaker effect on clopidogrel's pharmacokinetics and on platelet reactivity during concomitant use. 	Pantoprazole	clopidogrel	mechanism	{'e1': {'word': 'Pantoprazole', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d143.s4.e0'}, 'e2': {'word': 'clopidogrel', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d143.s4.e1'}, 'sentence_id': 'DDI-MedLine.d143.s4'}	DRUG has a much weaker effect on DRUGOTHER 's pharmacokinetics and on platelet reactivity during concomitant use .
The influence of the other proton pump inhibitors when used simultaneously with clopidogrel has not yet been investigated in adequately randomized studies. 	proton pump inhibitors	clopidogrel	none	{'e1': {'word': 'proton pump inhibitors', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d143.s5.e0'}, 'e2': {'word': 'clopidogrel', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d143.s5.e1'}, 'sentence_id': 'DDI-MedLine.d143.s5'}	The influence of the other DRUG when used simultaneously with DRUGOTHER has not yet been investigated in adequately randomized studies .
Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. 	clopidogrel	omeprazole	advise	{'e1': {'word': 'clopidogrel', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d143.s6.e0'}, 'e2': {'word': 'omeprazole', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d143.s6.e1'}, 'sentence_id': 'DDI-MedLine.d143.s6'}	Regulatory agencies state that the combination of DRUG and the CYP2C19 inhibitors DRUGOTHER and DRUGUNRELATED should be avoided .
Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. 	clopidogrel	esomeprazole	advise	{'e1': {'word': 'clopidogrel', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d143.s6.e0'}, 'e2': {'word': 'esomeprazole', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d143.s6.e2'}, 'sentence_id': 'DDI-MedLine.d143.s6'}	Regulatory agencies state that the combination of DRUG and the CYP2C19 inhibitors DRUGUNRELATED and DRUGOTHER should be avoided .
Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. 	omeprazole	esomeprazole	none	{'e1': {'word': 'omeprazole', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d143.s6.e1'}, 'e2': {'word': 'esomeprazole', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d143.s6.e2'}, 'sentence_id': 'DDI-MedLine.d143.s6'}	Regulatory agencies state that the combination of DRUGUNRELATED and the CYP2C19 inhibitors DRUG and DRUGOTHER should be avoided .
To date, there is no conclusive evidence of a clinically-relevant interaction between any of the proton pump inhibitors and clopidogrel.	proton pump inhibitors	clopidogrel	none	{'e1': {'word': 'proton pump inhibitors', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d143.s7.e0'}, 'e2': {'word': 'clopidogrel', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d143.s7.e1'}, 'sentence_id': 'DDI-MedLine.d143.s7'}	To date , there is no conclusive evidence of a clinically - relevant interaction between any of the DRUG and DRUGOTHER .
"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
"	lenalidomide	CCI-779	none	{'e1': {'word': 'lenalidomide', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d211.s0.e0'}, 'e2': {'word': 'CCI-779', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d211.s0.e1'}, 'sentence_id': 'DDI-MedLine.d211.s0'}	Phase I trial of DRUG and DRUGOTHER in patients with relapsed multiple myeloma : evidence for DRUGUNRELATED - DRUGUNRELATED interaction via P - glycoprotein .
"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
"	lenalidomide	lenalidomide	none	{'e1': {'word': 'lenalidomide', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d211.s0.e0'}, 'e2': {'word': 'lenalidomide', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d211.s0.e2'}, 'sentence_id': 'DDI-MedLine.d211.s0'}	Phase I trial of DRUG and DRUGUNRELATED in patients with relapsed multiple myeloma : evidence for DRUGOTHER - DRUGUNRELATED interaction via P - glycoprotein .
"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
"	lenalidomide	CCI-779	none	{'e1': {'word': 'lenalidomide', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d211.s0.e0'}, 'e2': {'word': 'CCI-779', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d211.s0.e3'}, 'sentence_id': 'DDI-MedLine.d211.s0'}	Phase I trial of DRUG and DRUGUNRELATED in patients with relapsed multiple myeloma : evidence for DRUGUNRELATED - DRUGOTHER interaction via P - glycoprotein .
"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
"	CCI-779	lenalidomide	none	{'e1': {'word': 'CCI-779', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d211.s0.e1'}, 'e2': {'word': 'lenalidomide', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d211.s0.e2'}, 'sentence_id': 'DDI-MedLine.d211.s0'}	Phase I trial of DRUGUNRELATED and DRUG in patients with relapsed multiple myeloma : evidence for DRUGOTHER - DRUGUNRELATED interaction via P - glycoprotein .
"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
"	CCI-779	CCI-779	none	{'e1': {'word': 'CCI-779', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d211.s0.e1'}, 'e2': {'word': 'CCI-779', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d211.s0.e3'}, 'sentence_id': 'DDI-MedLine.d211.s0'}	Phase I trial of DRUGUNRELATED and DRUG in patients with relapsed multiple myeloma : evidence for DRUGUNRELATED - DRUGOTHER interaction via P - glycoprotein .
"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
"	lenalidomide	CCI-779	none	{'e1': {'word': 'lenalidomide', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d211.s0.e2'}, 'e2': {'word': 'CCI-779', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d211.s0.e3'}, 'sentence_id': 'DDI-MedLine.d211.s0'}	Phase I trial of DRUGUNRELATED and DRUGUNRELATED in patients with relapsed multiple myeloma : evidence for DRUG - DRUGOTHER interaction via P - glycoprotein .
The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM.	lenalidomide	CCI-779	effect	{'e1': {'word': 'lenalidomide', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d211.s2.e0'}, 'e2': {'word': 'CCI-779', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d211.s2.e1'}, 'sentence_id': 'DDI-MedLine.d211.s2'}	The preclinical combination of DRUG with the mTOR inhibitor DRUGOTHER has displayed synergy in vitro and represents a novel combination in MM .
"The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
"	dasatinib	paclitaxel	effect	{'e1': {'word': 'dasatinib', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d194.s0.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d194.s0.e1'}, 'sentence_id': 'DDI-MedLine.d194.s0'}	The role of p27 ( Kip1 ) in DRUG - enhanced DRUGOTHER cytotoxicity in human ovarian cancer cells .
The effect of dasatinib, an inhibitor of Src and Abl kinases, on paclitaxel sensitivity was measured in ovarian cancer cells and HEY xenografts. 	dasatinib	paclitaxel	none	{'e1': {'word': 'dasatinib', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d194.s4.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d194.s4.e1'}, 'sentence_id': 'DDI-MedLine.d194.s4'}	The effect of DRUG , an inhibitor of Src and Abl kinases , on DRUGOTHER sensitivity was measured in ovarian cancer cells and HEY xenografts .
The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by dasatinib and paclitaxel were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry. 	dasatinib	paclitaxel	none	{'e1': {'word': 'dasatinib', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d194.s5.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d194.s5.e1'}, 'sentence_id': 'DDI-MedLine.d194.s5'}	The roles of p27 ( Kip1 ) , Bcl - 2 , and Cdk1 in apoptosis induced by DRUG and DRUGOTHER were assessed using a terminal deoxynucleotidyl transferase - mediated dUTP nick - end labeling ( TUNEL ) assay , siRNA knockdown of gene expression , transfection with Bcl - 2 and Cdk1 expression vectors , and flow cytometry .
HEY cells treated with dasatinib plus paclitaxel formed fewer colonies than did cells treated with either agent alone. 	dasatinib	paclitaxel	effect	{'e1': {'word': 'dasatinib', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d194.s9.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d194.s9.e1'}, 'sentence_id': 'DDI-MedLine.d194.s9'}	HEY cells treated with DRUG plus DRUGOTHER formed fewer colonies than did cells treated with either agent alone .
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	dasatinib	paclitaxel	effect	{'e1': {'word': 'dasatinib', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d194.s10.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d194.s10.e1'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	Treatment of HEY xenograft - bearing mice with DRUG plus DRUGOTHER inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , DRUGUNRELATED + DRUGUNRELATED vs DRUGUNRELATED : 0.28 vs . 0.81 cm3 , difference = 0.53 cm3 , 95 % confidence interval [ CI ] = 0.44 to 0.62 cm3 , P = .014 ) ;
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	dasatinib	dasatinib	none	{'e1': {'word': 'dasatinib', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d194.s10.e0'}, 'e2': {'word': 'dasatinib', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d194.s10.e2'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	Treatment of HEY xenograft - bearing mice with DRUG plus DRUGUNRELATED inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , DRUGOTHER + DRUGUNRELATED vs DRUGUNRELATED : 0.28 vs . 0.81 cm3 , difference = 0.53 cm3 , 95 % confidence interval [ CI ] = 0.44 to 0.62 cm3 , P = .014 ) ;
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	dasatinib	paclitaxel	none	{'e1': {'word': 'dasatinib', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d194.s10.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d194.s10.e3'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	Treatment of HEY xenograft - bearing mice with DRUG plus DRUGUNRELATED inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , DRUGUNRELATED + DRUGOTHER vs DRUGUNRELATED : 0.28 vs . 0.81 cm3 , difference = 0.53 cm3 , 95 % confidence interval [ CI ] = 0.44 to 0.62 cm3 , P = .014 ) ;
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	dasatinib	paclitaxel	none	{'e1': {'word': 'dasatinib', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d194.s10.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d194.s10.e4'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	Treatment of HEY xenograft - bearing mice with DRUG plus DRUGUNRELATED inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , DRUGUNRELATED + DRUGUNRELATED vs DRUGOTHER : 0.28 vs . 0.81 cm3 , difference = 0.53 cm3 , 95 % confidence interval [ CI ] = 0.44 to 0.62 cm3 , P = .014 ) ;
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	paclitaxel	dasatinib	none	{'e1': {'word': 'paclitaxel', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d194.s10.e1'}, 'e2': {'word': 'dasatinib', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d194.s10.e2'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	Treatment of HEY xenograft - bearing mice with DRUGUNRELATED plus DRUG inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , DRUGOTHER + DRUGUNRELATED vs DRUGUNRELATED : 0.28 vs . 0.81 cm3 , difference = 0.53 cm3 , 95 % confidence interval [ CI ] = 0.44 to 0.62 cm3 , P = .014 ) ;
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	paclitaxel	paclitaxel	none	{'e1': {'word': 'paclitaxel', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d194.s10.e1'}, 'e2': {'word': 'paclitaxel', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d194.s10.e3'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	Treatment of HEY xenograft - bearing mice with DRUGUNRELATED plus DRUG inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , DRUGUNRELATED + DRUGOTHER vs DRUGUNRELATED : 0.28 vs . 0.81 cm3 , difference = 0.53 cm3 , 95 % confidence interval [ CI ] = 0.44 to 0.62 cm3 , P = .014 ) ;
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	paclitaxel	paclitaxel	none	{'e1': {'word': 'paclitaxel', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d194.s10.e1'}, 'e2': {'word': 'paclitaxel', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d194.s10.e4'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	Treatment of HEY xenograft - bearing mice with DRUGUNRELATED plus DRUG inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , DRUGUNRELATED + DRUGUNRELATED vs DRUGOTHER : 0.28 vs . 0.81 cm3 , difference = 0.53 cm3 , 95 % confidence interval [ CI ] = 0.44 to 0.62 cm3 , P = .014 ) ;
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	dasatinib	paclitaxel	none	{'e1': {'word': 'dasatinib', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d194.s10.e2'}, 'e2': {'word': 'paclitaxel', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d194.s10.e3'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	Treatment of HEY xenograft - bearing mice with DRUGUNRELATED plus DRUGUNRELATED inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , DRUG + DRUGOTHER vs DRUGUNRELATED : 0.28 vs . 0.81 cm3 , difference = 0.53 cm3 , 95 % confidence interval [ CI ] = 0.44 to 0.62 cm3 , P = .014 ) ;
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	dasatinib	paclitaxel	none	{'e1': {'word': 'dasatinib', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d194.s10.e2'}, 'e2': {'word': 'paclitaxel', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d194.s10.e4'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	Treatment of HEY xenograft - bearing mice with DRUGUNRELATED plus DRUGUNRELATED inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , DRUG + DRUGUNRELATED vs DRUGOTHER : 0.28 vs . 0.81 cm3 , difference = 0.53 cm3 , 95 % confidence interval [ CI ] = 0.44 to 0.62 cm3 , P = .014 ) ;
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	paclitaxel	paclitaxel	none	{'e1': {'word': 'paclitaxel', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d194.s10.e3'}, 'e2': {'word': 'paclitaxel', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d194.s10.e4'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	Treatment of HEY xenograft - bearing mice with DRUGUNRELATED plus DRUGUNRELATED inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , DRUGUNRELATED + DRUG vs DRUGOTHER : 0.28 vs . 0.81 cm3 , difference = 0.53 cm3 , 95 % confidence interval [ CI ] = 0.44 to 0.62 cm3 , P = .014 ) ;
dasatinib + paclitaxel vs. 	dasatinib	paclitaxel	none	{'e1': {'word': 'dasatinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d194.s11.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d194.s11.e1'}, 'sentence_id': 'DDI-MedLine.d194.s11'}	DRUG + DRUGOTHER vs.
The siRNA knockdown of p27(Kip1) decreased dasatinib- and paclitaxel-induced apoptosis compared with a negative control siRNA (sub-G1 fraction, control siRNA vs. p27(Kip1) siRNA: 42.5% vs. 20.1%, difference = 22.4%, 95% CI = 20.1% to 24.7%, P = .017). 	dasatinib	paclitaxel	none	{'e1': {'word': 'dasatinib', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d194.s15.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d194.s15.e1'}, 'sentence_id': 'DDI-MedLine.d194.s15'}	The siRNA knockdown of p27 ( Kip1 ) decreased DRUG - and DRUGOTHER - induced apoptosis compared with a negative control siRNA ( sub-G1 fraction , control siRNA vs. p27 ( Kip1 ) siRNA : 42.5 % vs. 20.1 % , difference = 22.4 % , 95 % CI = 20.1 % to 24.7 % , P = .017 ) .
Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that dasatinib-mediated induction of p27(Kip1) enhanced paclitaxel-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression. 	dasatinib	paclitaxel	effect	{'e1': {'word': 'dasatinib', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d194.s16.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d194.s16.e1'}, 'sentence_id': 'DDI-MedLine.d194.s16'}	Studies with forced expression and siRNA knockdown of Bcl - 2 and Cdk1 suggest that DRUG - mediated induction of p27 ( Kip1 ) enhanced DRUGOTHER - induced apoptosis by negatively regulating Bcl - 2 and Cdk1 expression .
Inhibition of Src family and Abl kinases with either siRNAs or dasatinib enhances paclitaxel sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.	dasatinib	paclitaxel	effect	{'e1': {'word': 'dasatinib', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d194.s17.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d194.s17.e1'}, 'sentence_id': 'DDI-MedLine.d194.s17'}	Inhibition of Src family and Abl kinases with either siRNAs or DRUG enhances DRUGOTHER sensitivity of ovarian cancer cells through p27 ( Kip1 ) - mediated suppression of Bcl - 2 and Cdk1 expression .
[Efficacy of fixed combination amlodipine/valsartan in hospitalized patients with hypertensive disease]	amlodipine	valsartan	none	{'e1': {'word': 'amlodipine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d200.s0.e0'}, 'e2': {'word': 'valsartan', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d200.s0.e1'}, 'sentence_id': 'DDI-MedLine.d200.s0'}	[ Efficacy of fixed combination DRUG / DRUGOTHER in hospitalized patients with hypertensive disease ]
Efficacy and tolerability of fixed amlodipine/valsartan combination was studied in 86 patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology. 	amlodipine	valsartan	none	{'e1': {'word': 'amlodipine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d200.s1.e0'}, 'e2': {'word': 'valsartan', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d200.s1.e1'}, 'sentence_id': 'DDI-MedLine.d200.s1'}	Efficacy and tolerability of fixed DRUG / DRUGOTHER combination was studied in 86 patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology .
All patients had indications for antihypertensive therapy and were randomized either to fixed combination amlodipine/valsartan (n=43) or to therapy which corresponded to the hospital formulary (n=43). 	amlodipine	valsartan	none	{'e1': {'word': 'amlodipine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d200.s2.e0'}, 'e2': {'word': 'valsartan', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d200.s2.e1'}, 'sentence_id': 'DDI-MedLine.d200.s2'}	All patients had indications for antihypertensive therapy and were randomized either to fixed combination DRUG / DRUGOTHER ( n = 43 ) or to therapy which corresponded to the hospital formulary ( n = 43 ) .
Rate of achievement of target BP with fixed combination amlodipine/valsartan (93%) was comparable with that on traditional therapy (90%). 	amlodipine	valsartan	none	{'e1': {'word': 'amlodipine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d200.s7.e0'}, 'e2': {'word': 'valsartan', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d200.s7.e1'}, 'sentence_id': 'DDI-MedLine.d200.s7'}	Rate of achievement of target BP with fixed combination DRUG / DRUGOTHER ( 93 % ) was comparable with that on traditional therapy ( 90 % ) .
But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). 	amlodipine	valsartan	effect	{'e1': {'word': 'amlodipine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d200.s8.e0'}, 'e2': {'word': 'valsartan', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d200.s8.e1'}, 'sentence_id': 'DDI-MedLine.d200.s8'}	But the use of fixed combination DRUG / DRUGOTHER compared with traditional therapy was associated with lower clinical and self measured BP , quicker achievement of target BP ( 5.8 + / - 2.3 and 9.2 + / - 1.8 days , respectively , 0.05 ) , lesser number of DRUGUNRELATED ( 2.5 + / - 0.6 and 3.0 + / - 0.9 days , respectively ) , lower rate of concealed inefficacy of treatment ( 12 and 31 % , respectively , 0.05 ) .
But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). 	amlodipine	antihypertensive drugs	none	{'e1': {'word': 'amlodipine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d200.s8.e0'}, 'e2': {'word': 'antihypertensive drugs', 'word_index': [(50, 50)], 'id': 'DDI-MedLine.d200.s8.e2'}, 'sentence_id': 'DDI-MedLine.d200.s8'}	But the use of fixed combination DRUG / DRUGUNRELATED compared with traditional therapy was associated with lower clinical and self measured BP , quicker achievement of target BP ( 5.8 + / - 2.3 and 9.2 + / - 1.8 days , respectively , 0.05 ) , lesser number of DRUGOTHER ( 2.5 + / - 0.6 and 3.0 + / - 0.9 days , respectively ) , lower rate of concealed inefficacy of treatment ( 12 and 31 % , respectively , 0.05 ) .
But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). 	valsartan	antihypertensive drugs	none	{'e1': {'word': 'valsartan', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d200.s8.e1'}, 'e2': {'word': 'antihypertensive drugs', 'word_index': [(50, 50)], 'id': 'DDI-MedLine.d200.s8.e2'}, 'sentence_id': 'DDI-MedLine.d200.s8'}	But the use of fixed combination DRUGUNRELATED / DRUG compared with traditional therapy was associated with lower clinical and self measured BP , quicker achievement of target BP ( 5.8 + / - 2.3 and 9.2 + / - 1.8 days , respectively , 0.05 ) , lesser number of DRUGOTHER ( 2.5 + / - 0.6 and 3.0 + / - 0.9 days , respectively ) , lower rate of concealed inefficacy of treatment ( 12 and 31 % , respectively , 0.05 ) .
We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.	amlodipine	valsartan	effect	{'e1': {'word': 'amlodipine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d200.s10.e0'}, 'e2': {'word': 'valsartan', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d200.s10.e1'}, 'sentence_id': 'DDI-MedLine.d200.s10'}	We have demonstrated appropriateness of inhospital administration of fixed DRUG / DRUGOTHER combination as an approach allowing to achieve target BP in shorter time , with the use of fewer DRUGUNRELATED , and diminishing concealed inefficacy of treatment .
We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.	amlodipine	antihypertensive drugs	none	{'e1': {'word': 'amlodipine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d200.s10.e0'}, 'e2': {'word': 'antihypertensive drugs', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d200.s10.e2'}, 'sentence_id': 'DDI-MedLine.d200.s10'}	We have demonstrated appropriateness of inhospital administration of fixed DRUG / DRUGUNRELATED combination as an approach allowing to achieve target BP in shorter time , with the use of fewer DRUGOTHER , and diminishing concealed inefficacy of treatment .
We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.	valsartan	antihypertensive drugs	none	{'e1': {'word': 'valsartan', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d200.s10.e1'}, 'e2': {'word': 'antihypertensive drugs', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d200.s10.e2'}, 'sentence_id': 'DDI-MedLine.d200.s10'}	We have demonstrated appropriateness of inhospital administration of fixed DRUGUNRELATED / DRUG combination as an approach allowing to achieve target BP in shorter time , with the use of fewer DRUGOTHER , and diminishing concealed inefficacy of treatment .
The incubations were performed in the absence and presence of the non-specific CYP inhibitor, 1-aminobenzotriazole (ABT) and isoform-specific inhibitors. 	1-aminobenzotriazole	ABT	none	{'e1': {'word': '1-aminobenzotriazole', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d189.s3.e0'}, 'e2': {'word': 'ABT', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d189.s3.e1'}, 'sentence_id': 'DDI-MedLine.d189.s3'}	The incubations were performed in the absence and presence of the non-specific CYP inhibitor , DRUG ( DRUGOTHER ) and isoform - specific inhibitors .
ABT decreased the toxicity of precocene I, increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner. 	ABT	precocene I	effect	{'e1': {'word': 'ABT', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d189.s7.e0'}, 'e2': {'word': 'precocene I', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d189.s7.e1'}, 'sentence_id': 'DDI-MedLine.d189.s7'}	DRUG decreased the toxicity of DRUGOTHER , increased exposure to parent compound , and decreased metabolite levels in a dose - dependent manner .
Of the isoform-specific CYP inhibitors tested for an effect on the precocene I metabolite profile, only tranylcypromine was noticeably effective, indicating a role of CYPs 2A6, 2C9, 2Cl9, and 2E1. 	precocene I	tranylcypromine	none	{'e1': {'word': 'precocene I', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d189.s8.e0'}, 'e2': {'word': 'tranylcypromine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d189.s8.e1'}, 'sentence_id': 'DDI-MedLine.d189.s8'}	Of the isoform - specific CYP inhibitors tested for an effect on the DRUG metabolite profile , only DRUGOTHER was noticeably effective , indicating a role of CYPs 2A6 , 2C9 , 2Cl9 , and 2E1 .
With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. 	ABT	diethyldithiocarbamate	none	{'e1': {'word': 'ABT', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d189.s9.e0'}, 'e2': {'word': 'diethyldithiocarbamate', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d189.s9.e1'}, 'sentence_id': 'DDI-MedLine.d189.s9'}	With respect to toxicity , the order of CYP inhibitor effectiveness was DRUG > DRUGOTHER ~ DRUGUNRELATED > DRUGUNRELATED .
With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. 	ABT	tranylcypromine	none	{'e1': {'word': 'ABT', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d189.s9.e0'}, 'e2': {'word': 'tranylcypromine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d189.s9.e2'}, 'sentence_id': 'DDI-MedLine.d189.s9'}	With respect to toxicity , the order of CYP inhibitor effectiveness was DRUG > DRUGUNRELATED ~ DRUGOTHER > DRUGUNRELATED .
With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. 	ABT	ketoconazole	none	{'e1': {'word': 'ABT', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d189.s9.e0'}, 'e2': {'word': 'ketoconazole', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d189.s9.e3'}, 'sentence_id': 'DDI-MedLine.d189.s9'}	With respect to toxicity , the order of CYP inhibitor effectiveness was DRUG > DRUGUNRELATED ~ DRUGUNRELATED > DRUGOTHER .
With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. 	diethyldithiocarbamate	tranylcypromine	none	{'e1': {'word': 'diethyldithiocarbamate', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d189.s9.e1'}, 'e2': {'word': 'tranylcypromine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d189.s9.e2'}, 'sentence_id': 'DDI-MedLine.d189.s9'}	With respect to toxicity , the order of CYP inhibitor effectiveness was DRUGUNRELATED > DRUG ~ DRUGOTHER > DRUGUNRELATED .
With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. 	diethyldithiocarbamate	ketoconazole	none	{'e1': {'word': 'diethyldithiocarbamate', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d189.s9.e1'}, 'e2': {'word': 'ketoconazole', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d189.s9.e3'}, 'sentence_id': 'DDI-MedLine.d189.s9'}	With respect to toxicity , the order of CYP inhibitor effectiveness was DRUGUNRELATED > DRUG ~ DRUGUNRELATED > DRUGOTHER .
With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. 	tranylcypromine	ketoconazole	none	{'e1': {'word': 'tranylcypromine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d189.s9.e2'}, 'e2': {'word': 'ketoconazole', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d189.s9.e3'}, 'sentence_id': 'DDI-MedLine.d189.s9'}	With respect to toxicity , the order of CYP inhibitor effectiveness was DRUGUNRELATED > DRUGUNRELATED ~ DRUG > DRUGOTHER .
Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. 	Furafylline	sulfaphenazole	none	{'e1': {'word': 'Furafylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d189.s10.e0'}, 'e2': {'word': 'sulfaphenazole', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d189.s10.e1'}, 'sentence_id': 'DDI-MedLine.d189.s10'}	DRUG and DRUGOTHER had no effect , while DRUGUNRELATED appeared to augment DRUGUNRELATED toxicity .
Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. 	Furafylline	quinidine	none	{'e1': {'word': 'Furafylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d189.s10.e0'}, 'e2': {'word': 'quinidine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d189.s10.e2'}, 'sentence_id': 'DDI-MedLine.d189.s10'}	DRUG and DRUGUNRELATED had no effect , while DRUGOTHER appeared to augment DRUGUNRELATED toxicity .
Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. 	Furafylline	precocene I	none	{'e1': {'word': 'Furafylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d189.s10.e0'}, 'e2': {'word': 'precocene I', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d189.s10.e3'}, 'sentence_id': 'DDI-MedLine.d189.s10'}	DRUG and DRUGUNRELATED had no effect , while DRUGUNRELATED appeared to augment DRUGOTHER toxicity .
Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. 	sulfaphenazole	quinidine	none	{'e1': {'word': 'sulfaphenazole', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d189.s10.e1'}, 'e2': {'word': 'quinidine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d189.s10.e2'}, 'sentence_id': 'DDI-MedLine.d189.s10'}	DRUGUNRELATED and DRUG had no effect , while DRUGOTHER appeared to augment DRUGUNRELATED toxicity .
Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. 	sulfaphenazole	precocene I	none	{'e1': {'word': 'sulfaphenazole', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d189.s10.e1'}, 'e2': {'word': 'precocene I', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d189.s10.e3'}, 'sentence_id': 'DDI-MedLine.d189.s10'}	DRUGUNRELATED and DRUG had no effect , while DRUGUNRELATED appeared to augment DRUGOTHER toxicity .
Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. 	quinidine	precocene I	effect	{'e1': {'word': 'quinidine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d189.s10.e2'}, 'e2': {'word': 'precocene I', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d189.s10.e3'}, 'sentence_id': 'DDI-MedLine.d189.s10'}	DRUGUNRELATED and DRUGUNRELATED had no effect , while DRUG appeared to augment DRUGOTHER toxicity .
These results suggest that rat liver slices do not reproduce the reported in vivo biotransformation of precocene I and therefore may not be an appropriate model for precocene I metabolism. 	precocene I	precocene I	none	{'e1': {'word': 'precocene I', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d189.s11.e0'}, 'e2': {'word': 'precocene I', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d189.s11.e1'}, 'sentence_id': 'DDI-MedLine.d189.s11'}	These results suggest that rat liver slices do not reproduce the reported in vivo biotransformation of DRUG and therefore may not be an appropriate model for DRUGOTHER metabolism .
Calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.	Calcium	nonheme iron	none	{'e1': {'word': 'Calcium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s0.e0'}, 'e2': {'word': 'nonheme iron', 'word_index': [(10, 10), (13, 13)], 'id': 'DDI-MedLine.d169.s0.e1'}, 'sentence_id': 'DDI-MedLine.d169.s0'}	DRUG does not inhibit the absorption of 5 milligrams of DRUGOTHER or DRUGUNRELATED DRUGOTHER at doses less than 800 milligrams in nonpregnant women .
Calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.	Calcium	heme iron	none	{'e1': {'word': 'Calcium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s0.e0'}, 'e2': {'word': 'heme iron', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d169.s0.e2'}, 'sentence_id': 'DDI-MedLine.d169.s0'}	DRUG does not inhibit the absorption of 5 milligrams of DRUGUNRELATED or DRUGOTHER DRUGUNRELATED at doses less than 800 milligrams in nonpregnant women .
Calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.	nonheme iron	heme iron	none	{'e1': {'word': 'nonheme iron', 'word_index': [(10, 10), (13, 13)], 'id': 'DDI-MedLine.d169.s0.e1'}, 'e2': {'word': 'heme iron', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d169.s0.e2'}, 'sentence_id': 'DDI-MedLine.d169.s0'}	DRUGUNRELATED does not inhibit the absorption of 5 milligrams of DRUG or DRUGOTHER DRUG at doses less than 800 milligrams in nonpregnant women .
Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron. 	Calcium	nonheme iron	mechanism	{'e1': {'word': 'Calcium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s1.e0'}, 'e2': {'word': 'nonheme iron', 'word_index': [(15, 15), (18, 18)], 'id': 'DDI-MedLine.d169.s1.e1'}, 'sentence_id': 'DDI-MedLine.d169.s1'}	DRUG is the only known component in the diet that may affect absorption of both DRUGOTHER and DRUGUNRELATED DRUGOTHER .
Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron. 	Calcium	heme iron	mechanism	{'e1': {'word': 'Calcium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s1.e0'}, 'e2': {'word': 'heme iron', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d169.s1.e2'}, 'sentence_id': 'DDI-MedLine.d169.s1'}	DRUG is the only known component in the diet that may affect absorption of both DRUGUNRELATED and DRUGOTHER DRUGUNRELATED .
Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron. 	nonheme iron	heme iron	none	{'e1': {'word': 'nonheme iron', 'word_index': [(15, 15), (18, 18)], 'id': 'DDI-MedLine.d169.s1.e1'}, 'e2': {'word': 'heme iron', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d169.s1.e2'}, 'sentence_id': 'DDI-MedLine.d169.s1'}	DRUGUNRELATED is the only known component in the diet that may affect absorption of both DRUG and DRUGOTHER DRUG .
However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. 	calcium	iron	mechanism	{'e1': {'word': 'calcium', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d169.s2.e0'}, 'e2': {'word': 'iron', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d169.s2.e1'}, 'sentence_id': 'DDI-MedLine.d169.s2'}	However , the evidence for a DRUG effect on DRUGOTHER absorption mainly comes from studies that did not isolate the effect of DRUGUNRELATED from that of other dietary components , because it was detected in single - meal studies .
However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. 	calcium	calcium	none	{'e1': {'word': 'calcium', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d169.s2.e0'}, 'e2': {'word': 'calcium', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d169.s2.e2'}, 'sentence_id': 'DDI-MedLine.d169.s2'}	However , the evidence for a DRUG effect on DRUGUNRELATED absorption mainly comes from studies that did not isolate the effect of DRUGOTHER from that of other dietary components , because it was detected in single - meal studies .
However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. 	iron	calcium	none	{'e1': {'word': 'iron', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d169.s2.e1'}, 'e2': {'word': 'calcium', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d169.s2.e2'}, 'sentence_id': 'DDI-MedLine.d169.s2'}	However , the evidence for a DRUGUNRELATED effect on DRUG absorption mainly comes from studies that did not isolate the effect of DRUGOTHER from that of other dietary components , because it was detected in single - meal studies .
Our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal. 	calcium	nonheme iron	none	{'e1': {'word': 'calcium', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d169.s3.e0'}, 'e2': {'word': 'nonheme iron', 'word_index': [(12, 12), (15, 15)], 'id': 'DDI-MedLine.d169.s3.e1'}, 'sentence_id': 'DDI-MedLine.d169.s3'}	Our objective was to establish potential effects of DRUG on absorption of DRUGOTHER and DRUGUNRELATED DRUGOTHER and the dose response for this effect in the absence of a meal .
Our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal. 	calcium	heme iron	none	{'e1': {'word': 'calcium', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d169.s3.e0'}, 'e2': {'word': 'heme iron', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d169.s3.e2'}, 'sentence_id': 'DDI-MedLine.d169.s3'}	Our objective was to establish potential effects of DRUG on absorption of DRUGUNRELATED and DRUGOTHER DRUGUNRELATED and the dose response for this effect in the absence of a meal .
Our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal. 	nonheme iron	heme iron	none	{'e1': {'word': 'nonheme iron', 'word_index': [(12, 12), (15, 15)], 'id': 'DDI-MedLine.d169.s3.e1'}, 'e2': {'word': 'heme iron', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d169.s3.e2'}, 'sentence_id': 'DDI-MedLine.d169.s3'}	Our objective was to establish potential effects of DRUGUNRELATED on absorption of DRUG and DRUGOTHER DRUG and the dose response for this effect in the absence of a meal .
We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate). 	calcium	nonheme iron	none	{'e1': {'word': 'calcium', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d169.s5.e0'}, 'e2': {'word': 'nonheme iron', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d169.s5.e1'}, 'sentence_id': 'DDI-MedLine.d169.s5'}	We evaluated the effects of DRUG doses between 200 and 1500 mg on absorption of 5 mg DRUGOTHER ( as DRUGUNRELATED ) .
We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate). 	calcium	ferrous sulfate	none	{'e1': {'word': 'calcium', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d169.s5.e0'}, 'e2': {'word': 'ferrous sulfate', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d169.s5.e2'}, 'sentence_id': 'DDI-MedLine.d169.s5'}	We evaluated the effects of DRUG doses between 200 and 1500 mg on absorption of 5 mg DRUGUNRELATED ( as DRUGOTHER ) .
We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate). 	nonheme iron	ferrous sulfate	none	{'e1': {'word': 'nonheme iron', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d169.s5.e1'}, 'e2': {'word': 'ferrous sulfate', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d169.s5.e2'}, 'sentence_id': 'DDI-MedLine.d169.s5'}	We evaluated the effects of DRUGUNRELATED doses between 200 and 1500 mg on absorption of 5 mg DRUG ( as DRUGOTHER ) .
We also evaluated the effects of calcium doses between 200 and 800 mg on absorption of 5 mg heme iron [as concentrated RBC (CRBC)]. 	calcium	heme iron	none	{'e1': {'word': 'calcium', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d169.s6.e0'}, 'e2': {'word': 'heme iron', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d169.s6.e1'}, 'sentence_id': 'DDI-MedLine.d169.s6'}	We also evaluated the effects of DRUG doses between 200 and 800 mg on absorption of 5 mg DRUGOTHER [ as concentrated RBC ( CRBC ) ] .
Calcium was administered as calcium chloride in all studies and minerals were ingested on an empty stomach. 	Calcium	calcium chloride	none	{'e1': {'word': 'Calcium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s7.e0'}, 'e2': {'word': 'calcium chloride', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d169.s7.e1'}, 'sentence_id': 'DDI-MedLine.d169.s7'}	DRUG was administered as DRUGOTHER in all studies and DRUGUNRELATED were ingested on an empty stomach .
Calcium was administered as calcium chloride in all studies and minerals were ingested on an empty stomach. 	Calcium	minerals	none	{'e1': {'word': 'Calcium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s7.e0'}, 'e2': {'word': 'minerals', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d169.s7.e2'}, 'sentence_id': 'DDI-MedLine.d169.s7'}	DRUG was administered as DRUGUNRELATED in all studies and DRUGOTHER were ingested on an empty stomach .
Calcium was administered as calcium chloride in all studies and minerals were ingested on an empty stomach. 	calcium chloride	minerals	none	{'e1': {'word': 'calcium chloride', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d169.s7.e1'}, 'e2': {'word': 'minerals', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d169.s7.e2'}, 'sentence_id': 'DDI-MedLine.d169.s7'}	DRUGUNRELATED was administered as DRUG in all studies and DRUGOTHER were ingested on an empty stomach .
Calcium doses   1000 mg diminished nonheme iron absorption by an average of 49.6%.	Calcium	nonheme iron	mechanism	{'e1': {'word': 'Calcium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s8.e0'}, 'e2': {'word': 'nonheme iron', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d169.s8.e1'}, 'sentence_id': 'DDI-MedLine.d169.s8'}	DRUG doses 1000 mg diminished DRUGOTHER absorption by an average of 49.6 % .
A calcium dose of 800 mg diminished absorption of 5 mg heme iron by 37.7%. 	calcium	heme iron	mechanism	{'e1': {'word': 'calcium', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d169.s9.e0'}, 'e2': {'word': 'heme iron', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d169.s9.e1'}, 'sentence_id': 'DDI-MedLine.d169.s9'}	A DRUG dose of 800 mg diminished absorption of 5 mg DRUGOTHER by 37.7 % .
In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. 	calcium	nonheme iron	mechanism	{'e1': {'word': 'calcium', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d169.s10.e0'}, 'e2': {'word': 'nonheme iron', 'word_index': [(23, 23), (34, 34)], 'id': 'DDI-MedLine.d169.s10.e1'}, 'sentence_id': 'DDI-MedLine.d169.s10'}	In conclusion , we demonstrated an isolated effect of DRUG ( as chloride ) on absorption of 5 mg of iron provided as DRUGOTHER ( as sulfate ) and DRUGUNRELATED ( as CRBC ) DRUGOTHER .
In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. 	calcium	heme iron	mechanism	{'e1': {'word': 'calcium', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d169.s10.e0'}, 'e2': {'word': 'heme iron', 'word_index': [(29, 29), (34, 34)], 'id': 'DDI-MedLine.d169.s10.e2'}, 'sentence_id': 'DDI-MedLine.d169.s10'}	In conclusion , we demonstrated an isolated effect of DRUG ( as chloride ) on absorption of 5 mg of iron provided as DRUGUNRELATED ( as sulfate ) and DRUGOTHER ( as CRBC ) DRUGOTHER .
In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. 	nonheme iron	heme iron	none	{'e1': {'word': 'nonheme iron', 'word_index': [(23, 23), (34, 34)], 'id': 'DDI-MedLine.d169.s10.e1'}, 'e2': {'word': 'heme iron', 'word_index': [(29, 29), (34, 34)], 'id': 'DDI-MedLine.d169.s10.e2'}, 'sentence_id': 'DDI-MedLine.d169.s10'}	In conclusion , we demonstrated an isolated effect of DRUGUNRELATED ( as chloride ) on absorption of 5 mg of iron provided as DRUG ( as sulfate ) and DRUGOTHER ( as CRBC ) DRUGEITHER .
"Ephedrine enhances the antinociceptive effect of dexmedetomidine in mice.
"	Ephedrine	dexmedetomidine	effect	{'e1': {'word': 'Ephedrine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d227.s0.e0'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d227.s0.e1'}, 'sentence_id': 'DDI-MedLine.d227.s0'}	DRUG enhances the antinociceptive effect of DRUGOTHER in mice .
The purpose of this study was to evaluate whether the psychostimulant drug ephedrine has any effect on dexmedetomidine-induced antinociception and locomotor inhibitor activity in mice in acute application.	ephedrine	dexmedetomidine	none	{'e1': {'word': 'ephedrine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d227.s2.e0'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d227.s2.e1'}, 'sentence_id': 'DDI-MedLine.d227.s2'}	The purpose of this study was to evaluate whether the psychostimulant drug DRUG has any effect on DRUGOTHER - induced antinociception and locomotor inhibitor activity in mice in acute application .
saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. 	ephedrine	dexmedetomidine	none	{'e1': {'word': 'ephedrine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d227.s6.e0'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d227.s6.e1'}, 'sentence_id': 'DDI-MedLine.d227.s6'}	saline + saline , DRUG ( 10 mg / kg ) + saline , saline + DRUGOTHER ( 15 g / kg ) and DRUGUNRELATED ( 10 mg / kg ) + DRUGUNRELATED ( 15 g / kg ) , intraperitoneally , 30 min before hot plate or holed open field tests .
saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. 	ephedrine	ephedrine	none	{'e1': {'word': 'ephedrine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d227.s6.e0'}, 'e2': {'word': 'ephedrine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d227.s6.e2'}, 'sentence_id': 'DDI-MedLine.d227.s6'}	saline + saline , DRUG ( 10 mg / kg ) + saline , saline + DRUGUNRELATED ( 15 g / kg ) and DRUGOTHER ( 10 mg / kg ) + DRUGUNRELATED ( 15 g / kg ) , intraperitoneally , 30 min before hot plate or holed open field tests .
saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. 	ephedrine	dexmedetomidine	none	{'e1': {'word': 'ephedrine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d227.s6.e0'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d227.s6.e3'}, 'sentence_id': 'DDI-MedLine.d227.s6'}	saline + saline , DRUG ( 10 mg / kg ) + saline , saline + DRUGUNRELATED ( 15 g / kg ) and DRUGUNRELATED ( 10 mg / kg ) + DRUGOTHER ( 15 g / kg ) , intraperitoneally , 30 min before hot plate or holed open field tests .
saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. 	dexmedetomidine	ephedrine	none	{'e1': {'word': 'dexmedetomidine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d227.s6.e1'}, 'e2': {'word': 'ephedrine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d227.s6.e2'}, 'sentence_id': 'DDI-MedLine.d227.s6'}	saline + saline , DRUGUNRELATED ( 10 mg / kg ) + saline , saline + DRUG ( 15 g / kg ) and DRUGOTHER ( 10 mg / kg ) + DRUGUNRELATED ( 15 g / kg ) , intraperitoneally , 30 min before hot plate or holed open field tests .
saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. 	dexmedetomidine	dexmedetomidine	none	{'e1': {'word': 'dexmedetomidine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d227.s6.e1'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d227.s6.e3'}, 'sentence_id': 'DDI-MedLine.d227.s6'}	saline + saline , DRUGUNRELATED ( 10 mg / kg ) + saline , saline + DRUG ( 15 g / kg ) and DRUGUNRELATED ( 10 mg / kg ) + DRUGOTHER ( 15 g / kg ) , intraperitoneally , 30 min before hot plate or holed open field tests .
saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. 	ephedrine	dexmedetomidine	none	{'e1': {'word': 'ephedrine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d227.s6.e2'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d227.s6.e3'}, 'sentence_id': 'DDI-MedLine.d227.s6'}	saline + saline , DRUGUNRELATED ( 10 mg / kg ) + saline , saline + DRUGUNRELATED ( 15 g / kg ) and DRUG ( 10 mg / kg ) + DRUGOTHER ( 15 g / kg ) , intraperitoneally , 30 min before hot plate or holed open field tests .
In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. 	dexmedetomidine	ephedrine	effect	{'e1': {'word': 'dexmedetomidine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d227.s7.e0'}, 'e2': {'word': 'ephedrine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d227.s7.e1'}, 'sentence_id': 'DDI-MedLine.d227.s7'}	In the hot plate test in mice , co-administration of 15 g / kg DRUG with 10 mg / kg DRUGOTHER intraperitoneally not only enhanced , but also prolonged the duration of antinociception induced by DRUGUNRELATED .
In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. 	dexmedetomidine	dexmedetomidine	none	{'e1': {'word': 'dexmedetomidine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d227.s7.e0'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d227.s7.e2'}, 'sentence_id': 'DDI-MedLine.d227.s7'}	In the hot plate test in mice , co-administration of 15 g / kg DRUG with 10 mg / kg DRUGUNRELATED intraperitoneally not only enhanced , but also prolonged the duration of antinociception induced by DRUGOTHER .
In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. 	ephedrine	dexmedetomidine	none	{'e1': {'word': 'ephedrine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d227.s7.e1'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d227.s7.e2'}, 'sentence_id': 'DDI-MedLine.d227.s7'}	In the hot plate test in mice , co-administration of 15 g / kg DRUGUNRELATED with 10 mg / kg DRUG intraperitoneally not only enhanced , but also prolonged the duration of antinociception induced by DRUGOTHER .
At the same time, the locomotor inhibitory effect of dexmedetomidine was counteracted by ephedrine. 	dexmedetomidine	ephedrine	effect	{'e1': {'word': 'dexmedetomidine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d227.s8.e0'}, 'e2': {'word': 'ephedrine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d227.s8.e1'}, 'sentence_id': 'DDI-MedLine.d227.s8'}	At the same time , the locomotor inhibitory effect of DRUG was counteracted by DRUGOTHER .
We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	dexmedetomidine	ephedrine	effect	{'e1': {'word': 'dexmedetomidine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d227.s9.e0'}, 'e2': {'word': 'ephedrine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d227.s9.e1'}, 'sentence_id': 'DDI-MedLine.d227.s9'}	We concluded that the combined administration of DRUG with DRUGOTHER may have beneficial effects in the treatment of pain without causing sedation , which limits the use of DRUGUNRELATED as an DRUGUNRELATED in humans .
We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	dexmedetomidine	dexmedetomidine	none	{'e1': {'word': 'dexmedetomidine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d227.s9.e0'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d227.s9.e2'}, 'sentence_id': 'DDI-MedLine.d227.s9'}	We concluded that the combined administration of DRUG with DRUGUNRELATED may have beneficial effects in the treatment of pain without causing sedation , which limits the use of DRUGOTHER as an DRUGUNRELATED in humans .
We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	dexmedetomidine	analgesic	none	{'e1': {'word': 'dexmedetomidine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d227.s9.e0'}, 'e2': {'word': 'analgesic', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d227.s9.e3'}, 'sentence_id': 'DDI-MedLine.d227.s9'}	We concluded that the combined administration of DRUG with DRUGUNRELATED may have beneficial effects in the treatment of pain without causing sedation , which limits the use of DRUGUNRELATED as an DRUGOTHER in humans .
We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	ephedrine	dexmedetomidine	none	{'e1': {'word': 'ephedrine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d227.s9.e1'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d227.s9.e2'}, 'sentence_id': 'DDI-MedLine.d227.s9'}	We concluded that the combined administration of DRUGUNRELATED with DRUG may have beneficial effects in the treatment of pain without causing sedation , which limits the use of DRUGOTHER as an DRUGUNRELATED in humans .
We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	ephedrine	analgesic	none	{'e1': {'word': 'ephedrine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d227.s9.e1'}, 'e2': {'word': 'analgesic', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d227.s9.e3'}, 'sentence_id': 'DDI-MedLine.d227.s9'}	We concluded that the combined administration of DRUGUNRELATED with DRUG may have beneficial effects in the treatment of pain without causing sedation , which limits the use of DRUGUNRELATED as an DRUGOTHER in humans .
We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	dexmedetomidine	analgesic	none	{'e1': {'word': 'dexmedetomidine', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d227.s9.e2'}, 'e2': {'word': 'analgesic', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d227.s9.e3'}, 'sentence_id': 'DDI-MedLine.d227.s9'}	We concluded that the combined administration of DRUGUNRELATED with DRUGUNRELATED may have beneficial effects in the treatment of pain without causing sedation , which limits the use of DRUG as an DRUGOTHER in humans .
"Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.
"	Lapatinib	herceptin	effect	{'e1': {'word': 'Lapatinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d164.s0.e0'}, 'e2': {'word': 'herceptin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d164.s0.e1'}, 'sentence_id': 'DDI-MedLine.d164.s0'}	DRUG enhances DRUGOTHER - mediated antibody - dependent cellular cytotoxicity by up - regulation of cell surface HER2 expression .
Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	lapatinib	Herceptin	effect	{'e1': {'word': 'lapatinib', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d164.s1.e0'}, 'e2': {'word': 'Herceptin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d164.s1.e1'}, 'sentence_id': 'DDI-MedLine.d164.s1'}	Although it was previously reported that DRUG combined with DRUGOTHER improved the progression - free survival rate compared with DRUGUNRELATED alone for patients with DRUGUNRELATED - refractory HER2 - positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents .
Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	lapatinib	lapatinib	none	{'e1': {'word': 'lapatinib', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d164.s1.e0'}, 'e2': {'word': 'lapatinib', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d164.s1.e2'}, 'sentence_id': 'DDI-MedLine.d164.s1'}	Although it was previously reported that DRUG combined with DRUGUNRELATED improved the progression - free survival rate compared with DRUGOTHER alone for patients with DRUGUNRELATED - refractory HER2 - positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents .
Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	lapatinib	Herceptin	none	{'e1': {'word': 'lapatinib', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d164.s1.e0'}, 'e2': {'word': 'Herceptin', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d164.s1.e3'}, 'sentence_id': 'DDI-MedLine.d164.s1'}	Although it was previously reported that DRUG combined with DRUGUNRELATED improved the progression - free survival rate compared with DRUGUNRELATED alone for patients with DRUGOTHER - refractory HER2 - positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents .
Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	Herceptin	lapatinib	none	{'e1': {'word': 'Herceptin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d164.s1.e1'}, 'e2': {'word': 'lapatinib', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d164.s1.e2'}, 'sentence_id': 'DDI-MedLine.d164.s1'}	Although it was previously reported that DRUGUNRELATED combined with DRUG improved the progression - free survival rate compared with DRUGOTHER alone for patients with DRUGUNRELATED - refractory HER2 - positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents .
Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	Herceptin	Herceptin	none	{'e1': {'word': 'Herceptin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d164.s1.e1'}, 'e2': {'word': 'Herceptin', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d164.s1.e3'}, 'sentence_id': 'DDI-MedLine.d164.s1'}	Although it was previously reported that DRUGUNRELATED combined with DRUG improved the progression - free survival rate compared with DRUGUNRELATED alone for patients with DRUGOTHER - refractory HER2 - positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents .
Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	lapatinib	Herceptin	none	{'e1': {'word': 'lapatinib', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d164.s1.e2'}, 'e2': {'word': 'Herceptin', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d164.s1.e3'}, 'sentence_id': 'DDI-MedLine.d164.s1'}	Although it was previously reported that DRUGUNRELATED combined with DRUGUNRELATED improved the progression - free survival rate compared with DRUG alone for patients with DRUGOTHER - refractory HER2 - positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents .
We evaluated how lapatinib interacts with Herceptin in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC). 	lapatinib	Herceptin	none	{'e1': {'word': 'lapatinib', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d164.s2.e0'}, 'e2': {'word': 'Herceptin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d164.s2.e1'}, 'sentence_id': 'DDI-MedLine.d164.s2'}	We evaluated how DRUG interacts with DRUGOTHER in HER2 - positive breast cancer , with a particular focus on DRUGUNRELATED - mediated antibody - dependent cellular cytotoxicity ( ADCC ) .
We evaluated how lapatinib interacts with Herceptin in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC). 	lapatinib	Herceptin	none	{'e1': {'word': 'lapatinib', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d164.s2.e0'}, 'e2': {'word': 'Herceptin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d164.s2.e2'}, 'sentence_id': 'DDI-MedLine.d164.s2'}	We evaluated how DRUG interacts with DRUGUNRELATED in HER2 - positive breast cancer , with a particular focus on DRUGOTHER - mediated antibody - dependent cellular cytotoxicity ( ADCC ) .
We evaluated how lapatinib interacts with Herceptin in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC). 	Herceptin	Herceptin	none	{'e1': {'word': 'Herceptin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d164.s2.e1'}, 'e2': {'word': 'Herceptin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d164.s2.e2'}, 'sentence_id': 'DDI-MedLine.d164.s2'}	We evaluated how DRUGUNRELATED interacts with DRUG in HER2 - positive breast cancer , with a particular focus on DRUGOTHER - mediated antibody - dependent cellular cytotoxicity ( ADCC ) .
In an in vitro assay, lapatinib induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of Herceptin-mediated ADCC. 	lapatinib	Herceptin	effect	{'e1': {'word': 'lapatinib', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d164.s3.e0'}, 'e2': {'word': 'Herceptin', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d164.s3.e1'}, 'sentence_id': 'DDI-MedLine.d164.s3'}	In an in vitro assay , DRUG induced HER2 expression at the cell surface of HER2 - positive breast cancer cell lines , leading to the enhancement of DRUGOTHER - mediated ADCC .
Furthermore, we present a case report in which a second Herceptin treatment following lapatinib resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer. 	Herceptin	lapatinib	effect	{'e1': {'word': 'Herceptin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d164.s4.e0'}, 'e2': {'word': 'lapatinib', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d164.s4.e1'}, 'sentence_id': 'DDI-MedLine.d164.s4'}	Furthermore , we present a case report in which a second DRUG treatment following DRUGOTHER resulted in the marked shrinkage of multiple metastatic tumors in HER2 - positive breast cancer .
Lapatinib may have the potential to convert Herceptin-refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.	Lapatinib	Herceptin	none	{'e1': {'word': 'Lapatinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d164.s5.e0'}, 'e2': {'word': 'Herceptin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d164.s5.e1'}, 'sentence_id': 'DDI-MedLine.d164.s5'}	DRUG may have the potential to convert DRUGOTHER - refractory to DRUGUNRELATED - sensitive tumors in HER2 - positive breast cancer by up - regulation of the cell surface expression of HER2 .
Lapatinib may have the potential to convert Herceptin-refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.	Lapatinib	Herceptin	none	{'e1': {'word': 'Lapatinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d164.s5.e0'}, 'e2': {'word': 'Herceptin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d164.s5.e2'}, 'sentence_id': 'DDI-MedLine.d164.s5'}	DRUG may have the potential to convert DRUGUNRELATED - refractory to DRUGOTHER - sensitive tumors in HER2 - positive breast cancer by up - regulation of the cell surface expression of HER2 .
Lapatinib may have the potential to convert Herceptin-refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.	Herceptin	Herceptin	none	{'e1': {'word': 'Herceptin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d164.s5.e1'}, 'e2': {'word': 'Herceptin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d164.s5.e2'}, 'sentence_id': 'DDI-MedLine.d164.s5'}	DRUGUNRELATED may have the potential to convert DRUG - refractory to DRUGOTHER - sensitive tumors in HER2 - positive breast cancer by up - regulation of the cell surface expression of HER2 .
"In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients.
"	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d213.s0.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d213.s0.e1'}, 'sentence_id': 'DDI-MedLine.d213.s0'}	In vivo CYP3A activity is significantly lower in DRUG - treated as compared with DRUGOTHER - treated renal allograft recipients .
In vitro studies have identified cyclosporine and tacrolimus as CYP3A inhibitors. 	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d213.s1.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d213.s1.e1'}, 'sentence_id': 'DDI-MedLine.d213.s1'}	In vitro studies have identified DRUG and DRUGOTHER as CYP3A inhibitors .
Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). 	midazolam	cyclosporine	mechanism	{'e1': {'word': 'midazolam', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d213.s3.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d213.s3.e1'}, 'sentence_id': 'DDI-MedLine.d213.s3'}	Systemic and apparent oral DRUG clearance were 24 % ( 269 73 vs. 354 102 ml / min , P = 0.022 ) and 31 % ( 479 190 vs. 688 265 ml / min , P = 0.013 ) , respectively , lower in DRUGOTHER - treated patients ( n = 20 ) than in matched DRUGUNRELATED - treated patients ( n = 20 ) .
Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). 	midazolam	tacrolimus	none	{'e1': {'word': 'midazolam', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d213.s3.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(57, 57)], 'id': 'DDI-MedLine.d213.s3.e2'}, 'sentence_id': 'DDI-MedLine.d213.s3'}	Systemic and apparent oral DRUG clearance were 24 % ( 269 73 vs. 354 102 ml / min , P = 0.022 ) and 31 % ( 479 190 vs. 688 265 ml / min , P = 0.013 ) , respectively , lower in DRUGUNRELATED - treated patients ( n = 20 ) than in matched DRUGOTHER - treated patients ( n = 20 ) .
Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). 	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d213.s3.e1'}, 'e2': {'word': 'tacrolimus', 'word_index': [(57, 57)], 'id': 'DDI-MedLine.d213.s3.e2'}, 'sentence_id': 'DDI-MedLine.d213.s3'}	Systemic and apparent oral DRUGUNRELATED clearance were 24 % ( 269 73 vs. 354 102 ml / min , P = 0.022 ) and 31 % ( 479 190 vs. 688 265 ml / min , P = 0.013 ) , respectively , lower in DRUG - treated patients ( n = 20 ) than in matched DRUGOTHER - treated patients ( n = 20 ) .
The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). 	midazolam	tacrolimus	none	{'e1': {'word': 'midazolam', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d213.s4.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d213.s4.e1'}, 'sentence_id': 'DDI-MedLine.d213.s4'}	The latter displayed DRUG clearances similar to those in two larger cohorts of nonmatched DRUGOTHER - treated patients ( n = 58 and n = 80 ) and to those receiving a DRUGUNRELATED - free regimen ( n = 6 ) .
The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). 	midazolam	calcineurin inhibitor	none	{'e1': {'word': 'midazolam', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d213.s4.e0'}, 'e2': {'word': 'calcineurin inhibitor', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d213.s4.e2'}, 'sentence_id': 'DDI-MedLine.d213.s4'}	The latter displayed DRUG clearances similar to those in two larger cohorts of nonmatched DRUGUNRELATED - treated patients ( n = 58 and n = 80 ) and to those receiving a DRUGOTHER - free regimen ( n = 6 ) .
The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). 	tacrolimus	calcineurin inhibitor	none	{'e1': {'word': 'tacrolimus', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d213.s4.e1'}, 'e2': {'word': 'calcineurin inhibitor', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d213.s4.e2'}, 'sentence_id': 'DDI-MedLine.d213.s4'}	The latter displayed DRUGUNRELATED clearances similar to those in two larger cohorts of nonmatched DRUG - treated patients ( n = 58 and n = 80 ) and to those receiving a DRUGOTHER - free regimen ( n = 6 ) .
This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. 	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d213.s5.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d213.s5.e1'}, 'sentence_id': 'DDI-MedLine.d213.s5'}	This implies that in vivo hepatic and first - pass CYP3A activities are significantly lower in patients receiving DRUG than in those receiving DRUGOTHER , indicating that , at the doses generally used in clinical practice , DRUGUNRELATED is the stronger of the two with respect to CYP3A inhibition .
This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. 	cyclosporine	cyclosporine	none	{'e1': {'word': 'cyclosporine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d213.s5.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d213.s5.e2'}, 'sentence_id': 'DDI-MedLine.d213.s5'}	This implies that in vivo hepatic and first - pass CYP3A activities are significantly lower in patients receiving DRUG than in those receiving DRUGUNRELATED , indicating that , at the doses generally used in clinical practice , DRUGOTHER is the stronger of the two with respect to CYP3A inhibition .
This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. 	tacrolimus	cyclosporine	none	{'e1': {'word': 'tacrolimus', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d213.s5.e1'}, 'e2': {'word': 'cyclosporine', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d213.s5.e2'}, 'sentence_id': 'DDI-MedLine.d213.s5'}	This implies that in vivo hepatic and first - pass CYP3A activities are significantly lower in patients receiving DRUGUNRELATED than in those receiving DRUG , indicating that , at the doses generally used in clinical practice , DRUGOTHER is the stronger of the two with respect to CYP3A inhibition .
"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
"	ketoconazole	panobinostat	none	{'e1': {'word': 'ketoconazole', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d185.s0.e0'}, 'e2': {'word': 'panobinostat', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d185.s0.e1'}, 'sentence_id': 'DDI-MedLine.d185.s0'}	Effect of DRUG - mediated CYP3A4 inhibition on clinical pharmacokinetics of DRUGOTHER ( DRUGUNRELATED ) , an orally active DRUGUNRELATED .
"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
"	ketoconazole	LBH589	none	{'e1': {'word': 'ketoconazole', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d185.s0.e0'}, 'e2': {'word': 'LBH589', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d185.s0.e2'}, 'sentence_id': 'DDI-MedLine.d185.s0'}	Effect of DRUG - mediated CYP3A4 inhibition on clinical pharmacokinetics of DRUGUNRELATED ( DRUGOTHER ) , an orally active DRUGUNRELATED .
"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
"	ketoconazole	histone deacetylase inhibitor	none	{'e1': {'word': 'ketoconazole', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d185.s0.e0'}, 'e2': {'word': 'histone deacetylase inhibitor', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d185.s0.e3'}, 'sentence_id': 'DDI-MedLine.d185.s0'}	Effect of DRUG - mediated CYP3A4 inhibition on clinical pharmacokinetics of DRUGUNRELATED ( DRUGUNRELATED ) , an orally active DRUGOTHER .
"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
"	panobinostat	LBH589	none	{'e1': {'word': 'panobinostat', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d185.s0.e1'}, 'e2': {'word': 'LBH589', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d185.s0.e2'}, 'sentence_id': 'DDI-MedLine.d185.s0'}	Effect of DRUGUNRELATED - mediated CYP3A4 inhibition on clinical pharmacokinetics of DRUG ( DRUGOTHER ) , an orally active DRUGUNRELATED .
"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
"	panobinostat	histone deacetylase inhibitor	none	{'e1': {'word': 'panobinostat', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d185.s0.e1'}, 'e2': {'word': 'histone deacetylase inhibitor', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d185.s0.e3'}, 'sentence_id': 'DDI-MedLine.d185.s0'}	Effect of DRUGUNRELATED - mediated CYP3A4 inhibition on clinical pharmacokinetics of DRUG ( DRUGUNRELATED ) , an orally active DRUGOTHER .
"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
"	LBH589	histone deacetylase inhibitor	none	{'e1': {'word': 'LBH589', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d185.s0.e2'}, 'e2': {'word': 'histone deacetylase inhibitor', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d185.s0.e3'}, 'sentence_id': 'DDI-MedLine.d185.s0'}	Effect of DRUGUNRELATED - mediated CYP3A4 inhibition on clinical pharmacokinetics of DRUGUNRELATED ( DRUG ) , an orally active DRUGOTHER .
This study evaluated the effect of a potent CYP3A inhibitor, ketoconazole, on the pharmacokinetics and safety of panobinostat.	ketoconazole	panobinostat	none	{'e1': {'word': 'ketoconazole', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d185.s2.e0'}, 'e2': {'word': 'panobinostat', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d185.s2.e1'}, 'sentence_id': 'DDI-MedLine.d185.s2'}	This study evaluated the effect of a potent CYP3A inhibitor , DRUG , on the pharmacokinetics and safety of DRUGOTHER .
On day 8, a single panobinostat dose was co-administered with ketoconazole. 	panobinostat	ketoconazole	none	{'e1': {'word': 'panobinostat', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d185.s5.e0'}, 'e2': {'word': 'ketoconazole', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d185.s5.e1'}, 'sentence_id': 'DDI-MedLine.d185.s5'}	On day 8 , a single DRUG dose was co-administered with DRUGOTHER .
In the presence of ketoconazole, there was 1.6- and 1.8-fold increase in C (max) and AUC of panobinostat, respectively. 	ketoconazole	panobinostat	mechanism	{'e1': {'word': 'ketoconazole', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d185.s7.e0'}, 'e2': {'word': 'panobinostat', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d185.s7.e1'}, 'sentence_id': 'DDI-MedLine.d185.s7'}	In the presence of DRUG , there was 1.6 - and 1.8-fold increase in C ( max ) and AUC of DRUGOTHER , respectively .
Co-administration of panobinostat with CYP3A inhibitors is feasible as the observed increase in panobinostat PK parameters was not considered clinically relevant. 	panobinostat	panobinostat	none	{'e1': {'word': 'panobinostat', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d185.s12.e0'}, 'e2': {'word': 'panobinostat', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d185.s12.e1'}, 'sentence_id': 'DDI-MedLine.d185.s12'}	Co-administration of DRUG with CYP3A inhibitors is feasible as the observed increase in DRUGOTHER PK parameters was not considered clinically relevant .
Considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of panobinostat was not studied with CYP3A inhibitors, close monitoring of panobinostat-related adverse events is necessary.	panobinostat	panobinostat	none	{'e1': {'word': 'panobinostat', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d185.s13.e0'}, 'e2': {'word': 'panobinostat', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d185.s13.e1'}, 'sentence_id': 'DDI-MedLine.d185.s13'}	Considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of DRUG was not studied with CYP3A inhibitors , close monitoring of DRUGOTHER - related adverse events is necessary .
"Prevention of emergence agitation in seven children receiving low-dose ketamine and propofol total intravenous anesthesia.
"	ketamine	propofol	none	{'e1': {'word': 'ketamine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d199.s0.e0'}, 'e2': {'word': 'propofol', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d199.s0.e1'}, 'sentence_id': 'DDI-MedLine.d199.s0'}	Prevention of emergence agitation in seven children receiving low - dose DRUG and DRUGOTHER total intravenous anesthesia .
We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose ketamine in conjunction with propofol for total intravenous anesthesia (TIVA) repeatedly for radiation therapy. 	ketamine	propofol	none	{'e1': {'word': 'ketamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d199.s2.e0'}, 'e2': {'word': 'propofol', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d199.s2.e1'}, 'sentence_id': 'DDI-MedLine.d199.s2'}	We retrospectively reviewed the records of 7 pediatric oncology patients who received low - dose DRUG in conjunction with DRUGOTHER for total intravenous anesthesia ( TIVA ) repeatedly for radiation therapy .
EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol. 	propofol	ketamine	none	{'e1': {'word': 'propofol', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d199.s3.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d199.s3.e1'}, 'sentence_id': 'DDI-MedLine.d199.s3'}	EA signs were observed in all 7 patients in association with DRUG TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low - dose DRUGOTHER was added to DRUGUNRELATED .
EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol. 	propofol	propofol	none	{'e1': {'word': 'propofol', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d199.s3.e0'}, 'e2': {'word': 'propofol', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d199.s3.e2'}, 'sentence_id': 'DDI-MedLine.d199.s3'}	EA signs were observed in all 7 patients in association with DRUG TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low - dose DRUGUNRELATED was added to DRUGOTHER .
EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol. 	ketamine	propofol	none	{'e1': {'word': 'ketamine', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d199.s3.e1'}, 'e2': {'word': 'propofol', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d199.s3.e2'}, 'sentence_id': 'DDI-MedLine.d199.s3'}	EA signs were observed in all 7 patients in association with DRUGUNRELATED TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low - dose DRUG was added to DRUGOTHER .
Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.	ketamine	propofol	effect	{'e1': {'word': 'ketamine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d199.s4.e0'}, 'e2': {'word': 'propofol', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d199.s4.e1'}, 'sentence_id': 'DDI-MedLine.d199.s4'}	Based on this experience , we suggest that low - dose DRUG added to DRUGOTHER may be associated with prevention of EA in children with a history of EA with DRUGUNRELATED TIVA .
Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.	ketamine	propofol	none	{'e1': {'word': 'ketamine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d199.s4.e0'}, 'e2': {'word': 'propofol', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d199.s4.e2'}, 'sentence_id': 'DDI-MedLine.d199.s4'}	Based on this experience , we suggest that low - dose DRUG added to DRUGUNRELATED may be associated with prevention of EA in children with a history of EA with DRUGOTHER TIVA .
Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.	propofol	propofol	none	{'e1': {'word': 'propofol', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d199.s4.e1'}, 'e2': {'word': 'propofol', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d199.s4.e2'}, 'sentence_id': 'DDI-MedLine.d199.s4'}	Based on this experience , we suggest that low - dose DRUGUNRELATED added to DRUG may be associated with prevention of EA in children with a history of EA with DRUGOTHER TIVA .
Protective effect of acetyl-l-carnitine and  alpha lipoic acid against the acute toxicity of diepoxybutane to human lymphocytes.	acetyl-l-carnitine	alpha lipoic acid	none	{'e1': {'word': 'acetyl-l-carnitine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d159.s0.e0'}, 'e2': {'word': 'alpha lipoic acid', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d159.s0.e1'}, 'sentence_id': 'DDI-MedLine.d159.s0'}	Protective effect of DRUG and DRUGOTHER against the acute toxicity of diepoxybutane to human lymphocytes .
(ii) acetyl-l-carnitine elicits a significant protective effect on DEB induced toxicity, which was potentiated by  alpha-lipoic acid.	acetyl-l-carnitine	alpha-lipoic acid	effect	{'e1': {'word': 'acetyl-l-carnitine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d159.s6.e0'}, 'e2': {'word': 'alpha-lipoic acid', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d159.s6.e1'}, 'sentence_id': 'DDI-MedLine.d159.s6'}	( ii ) DRUG elicits a significant protective effect on DEB induced toxicity , which was potentiated by DRUGOTHER .
"Enhancement of humoral immune responses to inactivated Newcastle disease and avian influenza vaccines by oral administration of ginseng stem-and-leaf saponins in chickens.
"	avian influenza vaccines	ginseng stem-and-leaf saponins	none	{'e1': {'word': 'avian influenza vaccines', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d154.s0.e0'}, 'e2': {'word': 'ginseng stem-and-leaf saponins', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d154.s0.e1'}, 'sentence_id': 'DDI-MedLine.d154.s0'}	Enhancement of humoral immune responses to inactivated Newcastle disease and DRUG by oral administration of DRUGOTHER in chickens .
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. 	ginseng stem-and-leaf saponins	GSLS	none	{'e1': {'word': 'ginseng stem-and-leaf saponins', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d154.s2.e0'}, 'e2': {'word': 'GSLS', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d154.s2.e1'}, 'sentence_id': 'DDI-MedLine.d154.s2'}	The objective of this study was to evaluate the effect of oral administration of DRUG ( DRUGOTHER ) on the humoral immune responses of chickens to DRUGUNRELATED DRUGUNRELATED ND and DRUGUNRELATED DRUGUNRELATED .
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. 	ginseng stem-and-leaf saponins	inactivated ND vaccines	none	{'e1': {'word': 'ginseng stem-and-leaf saponins', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d154.s2.e0'}, 'e2': {'word': 'inactivated ND vaccines', 'word_index': [(26, 26), (31, 31)], 'id': 'DDI-MedLine.d154.s2.e2'}, 'sentence_id': 'DDI-MedLine.d154.s2'}	The objective of this study was to evaluate the effect of oral administration of DRUG ( DRUGUNRELATED ) on the humoral immune responses of chickens to DRUGOTHER DRUGUNRELATED ND and DRUGUNRELATED DRUGOTHER .
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. 	ginseng stem-and-leaf saponins	inactivated AI vaccines	none	{'e1': {'word': 'ginseng stem-and-leaf saponins', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d154.s2.e0'}, 'e2': {'word': 'inactivated AI vaccines', 'word_index': [(26, 26), (29, 29), (30, 30)], 'id': 'DDI-MedLine.d154.s2.e3'}, 'sentence_id': 'DDI-MedLine.d154.s2'}	The objective of this study was to evaluate the effect of oral administration of DRUG ( DRUGUNRELATED ) on the humoral immune responses of chickens to DRUGOTHER DRUGUNRELATED and DRUGOTHER DRUGOTHER .
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. 	GSLS	inactivated ND vaccines	none	{'e1': {'word': 'GSLS', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d154.s2.e1'}, 'e2': {'word': 'inactivated ND vaccines', 'word_index': [(26, 26), (31, 31)], 'id': 'DDI-MedLine.d154.s2.e2'}, 'sentence_id': 'DDI-MedLine.d154.s2'}	The objective of this study was to evaluate the effect of oral administration of DRUGUNRELATED ( DRUG ) on the humoral immune responses of chickens to DRUGOTHER DRUGUNRELATED ND and DRUGUNRELATED DRUGOTHER .
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. 	GSLS	inactivated AI vaccines	none	{'e1': {'word': 'GSLS', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d154.s2.e1'}, 'e2': {'word': 'inactivated AI vaccines', 'word_index': [(26, 26), (29, 29), (30, 30)], 'id': 'DDI-MedLine.d154.s2.e3'}, 'sentence_id': 'DDI-MedLine.d154.s2'}	The objective of this study was to evaluate the effect of oral administration of DRUGUNRELATED ( DRUG ) on the humoral immune responses of chickens to DRUGOTHER DRUGUNRELATED and DRUGOTHER DRUGOTHER .
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. 	inactivated ND vaccines	inactivated AI vaccines	none	{'e1': {'word': 'inactivated ND vaccines', 'word_index': [(26, 26), (31, 31)], 'id': 'DDI-MedLine.d154.s2.e2'}, 'e2': {'word': 'inactivated AI vaccines', 'word_index': [(27, 27), (30, 30), (31, 31)], 'id': 'DDI-MedLine.d154.s2.e3'}, 'sentence_id': 'DDI-MedLine.d154.s2'}	The objective of this study was to evaluate the effect of oral administration of DRUGUNRELATED ( DRUGUNRELATED ) on the humoral immune responses of chickens to DRUG DRUGOTHER ND and DRUGOTHER DRUGEITHER .
In experiment 1, oral administration of GSLS at a dose of 5 mg/kg of BW for 7 d on the immune response in chickens intramuscularly injected with inactivated ND vaccine was evaluated. 	GSLS	inactivated ND vaccine	none	{'e1': {'word': 'GSLS', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d154.s3.e0'}, 'e2': {'word': 'inactivated ND vaccine', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d154.s3.e1'}, 'sentence_id': 'DDI-MedLine.d154.s3'}	In experiment 1 , oral administration of DRUG at a dose of 5 mg / kg of BW for 7 d on the immune response in chickens intramuscularly injected with DRUGOTHER was evaluated .
In experiment 2, the same regimen of GSLS was administered to chickens inoculated with inactivated AI vaccines, and an enhanced serum antibody response to AI vaccination was also observed. 	GSLS	inactivated AI vaccines	effect	{'e1': {'word': 'GSLS', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d154.s5.e0'}, 'e2': {'word': 'inactivated AI vaccines', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d154.s5.e1'}, 'sentence_id': 'DDI-MedLine.d154.s5'}	In experiment 2 , the same regimen of DRUG was administered to chickens inoculated with DRUGOTHER , and an enhanced serum antibody response to AI vaccination was also observed .
Considering the safety of GSLS, because no adverse effect was found throughout the experiments, GSLS may be a promising oral adjuvant to improve immunization in poultry.	GSLS	GSLS	none	{'e1': {'word': 'GSLS', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d154.s6.e0'}, 'e2': {'word': 'GSLS', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d154.s6.e1'}, 'sentence_id': 'DDI-MedLine.d154.s6'}	Considering the safety of DRUG , because no adverse effect was found throughout the experiments , DRUGOTHER may be a promising oral adjuvant to improve immunization in poultry .
"Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.
"	S-ketamine	itraconazole	none	{'e1': {'word': 'S-ketamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d216.s0.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d216.s0.e1'}, 'sentence_id': 'DDI-MedLine.d216.s0'}	Exposure to oral DRUG is unaffected by DRUGOTHER but greatly increased by DRUGUNRELATED .
"Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.
"	S-ketamine	ticlopidine	effect	{'e1': {'word': 'S-ketamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d216.s0.e0'}, 'e2': {'word': 'ticlopidine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d216.s0.e2'}, 'sentence_id': 'DDI-MedLine.d216.s0'}	Exposure to oral DRUG is unaffected by DRUGUNRELATED but greatly increased by DRUGOTHER .
"Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.
"	itraconazole	ticlopidine	none	{'e1': {'word': 'itraconazole', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d216.s0.e1'}, 'e2': {'word': 'ticlopidine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d216.s0.e2'}, 'sentence_id': 'DDI-MedLine.d216.s0'}	Exposure to oral DRUGUNRELATED is unaffected by DRUG but greatly increased by DRUGOTHER .
This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. 	S-ketamine	ticlopidine	none	{'e1': {'word': 'S-ketamine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d216.s1.e0'}, 'e2': {'word': 'ticlopidine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d216.s1.e1'}, 'sentence_id': 'DDI-MedLine.d216.s1'}	This study examined drug - drug interactions of oral DRUG with the cytochrome P450 ( CYP ) 2B6 inhibitor DRUGOTHER and the CYP3A inhibitor DRUGUNRELATED .
This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. 	S-ketamine	itraconazole	none	{'e1': {'word': 'S-ketamine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d216.s1.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d216.s1.e2'}, 'sentence_id': 'DDI-MedLine.d216.s1'}	This study examined drug - drug interactions of oral DRUG with the cytochrome P450 ( CYP ) 2B6 inhibitor DRUGUNRELATED and the CYP3A inhibitor DRUGOTHER .
This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. 	ticlopidine	itraconazole	none	{'e1': {'word': 'ticlopidine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d216.s1.e1'}, 'e2': {'word': 'itraconazole', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d216.s1.e2'}, 'sentence_id': 'DDI-MedLine.d216.s1'}	This study examined drug - drug interactions of oral DRUGUNRELATED with the cytochrome P450 ( CYP ) 2B6 inhibitor DRUG and the CYP3A inhibitor DRUGOTHER .
In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. 	S-ketamine	ticlopidine	none	{'e1': {'word': 'S-ketamine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d216.s2.e0'}, 'e2': {'word': 'ticlopidine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d216.s2.e1'}, 'sentence_id': 'DDI-MedLine.d216.s2'}	In this randomized , blinded , crossover study , 11 healthy volunteers ingested 0.2 mg / kg DRUG after pretreatments with oral DRUGOTHER ( 250 mg twice daily ) , DRUGUNRELATED ( 200 mg once daily ) , or placebo in 6 - day treatment periods at intervals of 4 weeks .
In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. 	S-ketamine	itraconazole	none	{'e1': {'word': 'S-ketamine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d216.s2.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d216.s2.e2'}, 'sentence_id': 'DDI-MedLine.d216.s2'}	In this randomized , blinded , crossover study , 11 healthy volunteers ingested 0.2 mg / kg DRUG after pretreatments with oral DRUGUNRELATED ( 250 mg twice daily ) , DRUGOTHER ( 200 mg once daily ) , or placebo in 6 - day treatment periods at intervals of 4 weeks .
In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. 	ticlopidine	itraconazole	none	{'e1': {'word': 'ticlopidine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d216.s2.e1'}, 'e2': {'word': 'itraconazole', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d216.s2.e2'}, 'sentence_id': 'DDI-MedLine.d216.s2'}	In this randomized , blinded , crossover study , 11 healthy volunteers ingested 0.2 mg / kg DRUGUNRELATED after pretreatments with oral DRUG ( 250 mg twice daily ) , DRUGOTHER ( 200 mg once daily ) , or placebo in 6 - day treatment periods at intervals of 4 weeks .
Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. 	Ticlopidine	ketamine	mechanism	{'e1': {'word': 'Ticlopidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d216.s3.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d216.s3.e1'}, 'sentence_id': 'DDI-MedLine.d216.s3'}	DRUG treatment increased the mean area under the plasma concentration - time curve extrapolated to infinity ( AUC ( 0 - ) ) of oral DRUGOTHER by 2.4-fold , whereas DRUGUNRELATED treatment did not increase the exposure to DRUGUNRELATED .
Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. 	Ticlopidine	itraconazole	none	{'e1': {'word': 'Ticlopidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d216.s3.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d216.s3.e2'}, 'sentence_id': 'DDI-MedLine.d216.s3'}	DRUG treatment increased the mean area under the plasma concentration - time curve extrapolated to infinity ( AUC ( 0 - ) ) of oral DRUGUNRELATED by 2.4-fold , whereas DRUGOTHER treatment did not increase the exposure to DRUGUNRELATED .
Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. 	Ticlopidine	S-ketamine	none	{'e1': {'word': 'Ticlopidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d216.s3.e0'}, 'e2': {'word': 'S-ketamine', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d216.s3.e3'}, 'sentence_id': 'DDI-MedLine.d216.s3'}	DRUG treatment increased the mean area under the plasma concentration - time curve extrapolated to infinity ( AUC ( 0 - ) ) of oral DRUGUNRELATED by 2.4-fold , whereas DRUGUNRELATED treatment did not increase the exposure to DRUGOTHER .
Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. 	ketamine	itraconazole	none	{'e1': {'word': 'ketamine', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d216.s3.e1'}, 'e2': {'word': 'itraconazole', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d216.s3.e2'}, 'sentence_id': 'DDI-MedLine.d216.s3'}	DRUGUNRELATED treatment increased the mean area under the plasma concentration - time curve extrapolated to infinity ( AUC ( 0 - ) ) of oral DRUG by 2.4-fold , whereas DRUGOTHER treatment did not increase the exposure to DRUGUNRELATED .
Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. 	ketamine	S-ketamine	none	{'e1': {'word': 'ketamine', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d216.s3.e1'}, 'e2': {'word': 'S-ketamine', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d216.s3.e3'}, 'sentence_id': 'DDI-MedLine.d216.s3'}	DRUGUNRELATED treatment increased the mean area under the plasma concentration - time curve extrapolated to infinity ( AUC ( 0 - ) ) of oral DRUG by 2.4-fold , whereas DRUGUNRELATED treatment did not increase the exposure to DRUGOTHER .
Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. 	itraconazole	S-ketamine	none	{'e1': {'word': 'itraconazole', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d216.s3.e2'}, 'e2': {'word': 'S-ketamine', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d216.s3.e3'}, 'sentence_id': 'DDI-MedLine.d216.s3'}	DRUGUNRELATED treatment increased the mean area under the plasma concentration - time curve extrapolated to infinity ( AUC ( 0 - ) ) of oral DRUGUNRELATED by 2.4-fold , whereas DRUG treatment did not increase the exposure to DRUGOTHER .
The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. 	norketamine	ketamine	none	{'e1': {'word': 'norketamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d216.s4.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d216.s4.e1'}, 'sentence_id': 'DDI-MedLine.d216.s4'}	The ratio of DRUG AUC ( 0 - ) to DRUGOTHER AUC ( 0 - ) was significantly decreased in the DRUGUNRELATED ( P &lt ; 0.001 ) and DRUGUNRELATED phases ( P = 0.006 ) as compared to placebo .
The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. 	norketamine	ticlopidine	none	{'e1': {'word': 'norketamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d216.s4.e0'}, 'e2': {'word': 'ticlopidine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d216.s4.e2'}, 'sentence_id': 'DDI-MedLine.d216.s4'}	The ratio of DRUG AUC ( 0 - ) to DRUGUNRELATED AUC ( 0 - ) was significantly decreased in the DRUGOTHER ( P &lt ; 0.001 ) and DRUGUNRELATED phases ( P = 0.006 ) as compared to placebo .
The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. 	norketamine	itraconazole	none	{'e1': {'word': 'norketamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d216.s4.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d216.s4.e3'}, 'sentence_id': 'DDI-MedLine.d216.s4'}	The ratio of DRUG AUC ( 0 - ) to DRUGUNRELATED AUC ( 0 - ) was significantly decreased in the DRUGUNRELATED ( P &lt ; 0.001 ) and DRUGOTHER phases ( P = 0.006 ) as compared to placebo .
The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. 	ketamine	ticlopidine	none	{'e1': {'word': 'ketamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d216.s4.e1'}, 'e2': {'word': 'ticlopidine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d216.s4.e2'}, 'sentence_id': 'DDI-MedLine.d216.s4'}	The ratio of DRUGUNRELATED AUC ( 0 - ) to DRUG AUC ( 0 - ) was significantly decreased in the DRUGOTHER ( P &lt ; 0.001 ) and DRUGUNRELATED phases ( P = 0.006 ) as compared to placebo .
The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. 	ketamine	itraconazole	none	{'e1': {'word': 'ketamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d216.s4.e1'}, 'e2': {'word': 'itraconazole', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d216.s4.e3'}, 'sentence_id': 'DDI-MedLine.d216.s4'}	The ratio of DRUGUNRELATED AUC ( 0 - ) to DRUG AUC ( 0 - ) was significantly decreased in the DRUGUNRELATED ( P &lt ; 0.001 ) and DRUGOTHER phases ( P = 0.006 ) as compared to placebo .
The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. 	ticlopidine	itraconazole	none	{'e1': {'word': 'ticlopidine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d216.s4.e2'}, 'e2': {'word': 'itraconazole', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d216.s4.e3'}, 'sentence_id': 'DDI-MedLine.d216.s4'}	The ratio of DRUGUNRELATED AUC ( 0 - ) to DRUGUNRELATED AUC ( 0 - ) was significantly decreased in the DRUG ( P &lt ; 0.001 ) and DRUGOTHER phases ( P = 0.006 ) as compared to placebo .
In the ticlopidine and itraconazole phases, the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (P < 0.05). 	ticlopidine	itraconazole	none	{'e1': {'word': 'ticlopidine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d216.s5.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d216.s5.e1'}, 'sentence_id': 'DDI-MedLine.d216.s5'}	In the DRUG and DRUGOTHER phases , the areas under the effect - time curves ( self - reported drowsiness and performance ) were significantly higher than those in the placebo phase ( P < 0.05 ) .
The findings suggest that the dosage of S-ketamine should be reduced in patients receiving ticlopidine.	S-ketamine	ticlopidine	advise	{'e1': {'word': 'S-ketamine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d216.s6.e0'}, 'e2': {'word': 'ticlopidine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d216.s6.e1'}, 'sentence_id': 'DDI-MedLine.d216.s6'}	The findings suggest that the dosage of DRUG should be reduced in patients receiving DRUGOTHER .
"Distinct synergistic action of piperacillin and methylglyoxal against Pseudomonas aeruginosa.
"	piperacillin	methylglyoxal	none	{'e1': {'word': 'piperacillin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d204.s0.e0'}, 'e2': {'word': 'methylglyoxal', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d204.s0.e1'}, 'sentence_id': 'DDI-MedLine.d204.s0'}	Distinct synergistic action of DRUG and DRUGOTHER against Pseudomonas aeruginosa .
Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. 	piperacillin	carbenicillin	none	{'e1': {'word': 'piperacillin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d204.s7.e0'}, 'e2': {'word': 'carbenicillin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d204.s7.e1'}, 'sentence_id': 'DDI-MedLine.d204.s7'}	Results revealed that the strains were resistant to many drugs at high levels , only DRUG , DRUGOTHER , DRUGUNRELATED and DRUGUNRELATED showed resistances at comparatively lower levels .
Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. 	piperacillin	amikacin	none	{'e1': {'word': 'piperacillin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d204.s7.e0'}, 'e2': {'word': 'amikacin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d204.s7.e2'}, 'sentence_id': 'DDI-MedLine.d204.s7'}	Results revealed that the strains were resistant to many drugs at high levels , only DRUG , DRUGUNRELATED , DRUGOTHER and DRUGUNRELATED showed resistances at comparatively lower levels .
Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. 	piperacillin	ciprofloxacin	none	{'e1': {'word': 'piperacillin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d204.s7.e0'}, 'e2': {'word': 'ciprofloxacin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d204.s7.e3'}, 'sentence_id': 'DDI-MedLine.d204.s7'}	Results revealed that the strains were resistant to many drugs at high levels , only DRUG , DRUGUNRELATED , DRUGUNRELATED and DRUGOTHER showed resistances at comparatively lower levels .
Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. 	carbenicillin	amikacin	none	{'e1': {'word': 'carbenicillin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d204.s7.e1'}, 'e2': {'word': 'amikacin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d204.s7.e2'}, 'sentence_id': 'DDI-MedLine.d204.s7'}	Results revealed that the strains were resistant to many drugs at high levels , only DRUGUNRELATED , DRUG , DRUGOTHER and DRUGUNRELATED showed resistances at comparatively lower levels .
Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. 	carbenicillin	ciprofloxacin	none	{'e1': {'word': 'carbenicillin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d204.s7.e1'}, 'e2': {'word': 'ciprofloxacin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d204.s7.e3'}, 'sentence_id': 'DDI-MedLine.d204.s7'}	Results revealed that the strains were resistant to many drugs at high levels , only DRUGUNRELATED , DRUG , DRUGUNRELATED and DRUGOTHER showed resistances at comparatively lower levels .
Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. 	amikacin	ciprofloxacin	none	{'e1': {'word': 'amikacin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d204.s7.e2'}, 'e2': {'word': 'ciprofloxacin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d204.s7.e3'}, 'sentence_id': 'DDI-MedLine.d204.s7'}	Results revealed that the strains were resistant to many drugs at high levels , only DRUGUNRELATED , DRUGUNRELATED , DRUG and DRUGOTHER showed resistances at comparatively lower levels .
Distinct and statistically significant synergism was observed between methylglyoxal and piperacillin by disc diffusion tests when compared with their individual effects. 	methylglyoxal	piperacillin	effect	{'e1': {'word': 'methylglyoxal', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d204.s9.e0'}, 'e2': {'word': 'piperacillin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d204.s9.e1'}, 'sentence_id': 'DDI-MedLine.d204.s9'}	Distinct and statistically significant synergism was observed between DRUG and DRUGOTHER by disc diffusion tests when compared with their individual effects .
Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.	methylglyoxal	carbenicillin	effect	{'e1': {'word': 'methylglyoxal', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d204.s11.e0'}, 'e2': {'word': 'carbenicillin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d204.s11.e1'}, 'sentence_id': 'DDI-MedLine.d204.s11'}	Synergism was also noted when DRUG was combined with DRUGOTHER and DRUGUNRELATED .
Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.	methylglyoxal	amikacin	effect	{'e1': {'word': 'methylglyoxal', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d204.s11.e0'}, 'e2': {'word': 'amikacin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d204.s11.e2'}, 'sentence_id': 'DDI-MedLine.d204.s11'}	Synergism was also noted when DRUG was combined with DRUGUNRELATED and DRUGOTHER .
Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.	carbenicillin	amikacin	none	{'e1': {'word': 'carbenicillin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d204.s11.e1'}, 'e2': {'word': 'amikacin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d204.s11.e2'}, 'sentence_id': 'DDI-MedLine.d204.s11'}	Synergism was also noted when DRUGUNRELATED was combined with DRUG and DRUGOTHER .
The 3-Deazaneplanocin A (DZNep), one of S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors, has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia. 	3-Deazaneplanocin A	DZNep	none	{'e1': {'word': '3-Deazaneplanocin A', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d180.s1.e0'}, 'e2': {'word': 'DZNep', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d180.s1.e1'}, 'sentence_id': 'DDI-MedLine.d180.s1'}	The DRUG ( DRUGOTHER ) , one of S - adenosylhomocysteine ( AdoHcy ) hydrolase inhibitors , has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia .
We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 	DZNep	DZNep	none	{'e1': {'word': 'DZNep', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d180.s10.e0'}, 'e2': {'word': 'DZNep', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d180.s10.e1'}, 'sentence_id': 'DDI-MedLine.d180.s10'}	We also found that Bcl - 2 was overexpressed in DRUG insensitive cells , and cotreatment with DRUGOTHER and DRUGUNRELATED , a Bcl - 2 family inhibitor , synergistically inhibited growth and induced apoptosis of DRUGUNRELATED insensitive MM cells .
We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 	DZNep	ABT-737	none	{'e1': {'word': 'DZNep', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d180.s10.e0'}, 'e2': {'word': 'ABT-737', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d180.s10.e2'}, 'sentence_id': 'DDI-MedLine.d180.s10'}	We also found that Bcl - 2 was overexpressed in DRUG insensitive cells , and cotreatment with DRUGUNRELATED and DRUGOTHER , a Bcl - 2 family inhibitor , synergistically inhibited growth and induced apoptosis of DRUGUNRELATED insensitive MM cells .
We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 	DZNep	DZNep	none	{'e1': {'word': 'DZNep', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d180.s10.e0'}, 'e2': {'word': 'DZNep', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d180.s10.e3'}, 'sentence_id': 'DDI-MedLine.d180.s10'}	We also found that Bcl - 2 was overexpressed in DRUG insensitive cells , and cotreatment with DRUGUNRELATED and DRUGUNRELATED , a Bcl - 2 family inhibitor , synergistically inhibited growth and induced apoptosis of DRUGOTHER insensitive MM cells .
We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 	DZNep	ABT-737	effect	{'e1': {'word': 'DZNep', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d180.s10.e1'}, 'e2': {'word': 'ABT-737', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d180.s10.e2'}, 'sentence_id': 'DDI-MedLine.d180.s10'}	We also found that Bcl - 2 was overexpressed in DRUGUNRELATED insensitive cells , and cotreatment with DRUG and DRUGOTHER , a Bcl - 2 family inhibitor , synergistically inhibited growth and induced apoptosis of DRUGUNRELATED insensitive MM cells .
We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 	DZNep	DZNep	none	{'e1': {'word': 'DZNep', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d180.s10.e1'}, 'e2': {'word': 'DZNep', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d180.s10.e3'}, 'sentence_id': 'DDI-MedLine.d180.s10'}	We also found that Bcl - 2 was overexpressed in DRUGUNRELATED insensitive cells , and cotreatment with DRUG and DRUGUNRELATED , a Bcl - 2 family inhibitor , synergistically inhibited growth and induced apoptosis of DRUGOTHER insensitive MM cells .
We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 	ABT-737	DZNep	none	{'e1': {'word': 'ABT-737', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d180.s10.e2'}, 'e2': {'word': 'DZNep', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d180.s10.e3'}, 'sentence_id': 'DDI-MedLine.d180.s10'}	We also found that Bcl - 2 was overexpressed in DRUGUNRELATED insensitive cells , and cotreatment with DRUGUNRELATED and DRUG , a Bcl - 2 family inhibitor , synergistically inhibited growth and induced apoptosis of DRUGOTHER insensitive MM cells .
In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. 	DZNep	ABT-737	none	{'e1': {'word': 'DZNep', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d180.s12.e0'}, 'e2': {'word': 'ABT-737', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d180.s12.e1'}, 'sentence_id': 'DDI-MedLine.d180.s12'}	In addition , DRUG insensitivity might be associated with overexpression of Bcl - 2 , and the combination of DRUGOTHER and DRUGUNRELATED could synergistically induced apoptosis .
In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. 	DZNep	DZNep	none	{'e1': {'word': 'DZNep', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d180.s12.e0'}, 'e2': {'word': 'DZNep', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d180.s12.e2'}, 'sentence_id': 'DDI-MedLine.d180.s12'}	In addition , DRUG insensitivity might be associated with overexpression of Bcl - 2 , and the combination of DRUGUNRELATED and DRUGOTHER could synergistically induced apoptosis .
In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. 	ABT-737	DZNep	effect	{'e1': {'word': 'ABT-737', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d180.s12.e1'}, 'e2': {'word': 'DZNep', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d180.s12.e2'}, 'sentence_id': 'DDI-MedLine.d180.s12'}	In addition , DRUGUNRELATED insensitivity might be associated with overexpression of Bcl - 2 , and the combination of DRUG and DRUGOTHER could synergistically induced apoptosis .
"In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.
"	minocycline	fosfomycin	none	{'e1': {'word': 'minocycline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d163.s0.e0'}, 'e2': {'word': 'fosfomycin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d163.s0.e1'}, 'sentence_id': 'DDI-MedLine.d163.s0'}	In vitro activity of DRUG combined with DRUGOTHER against clinical isolates of DRUGUNRELATED - resistant Staphylococcus aureus .
"In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.
"	minocycline	methicillin	none	{'e1': {'word': 'minocycline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d163.s0.e0'}, 'e2': {'word': 'methicillin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d163.s0.e2'}, 'sentence_id': 'DDI-MedLine.d163.s0'}	In vitro activity of DRUG combined with DRUGUNRELATED against clinical isolates of DRUGOTHER - resistant Staphylococcus aureus .
"In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.
"	fosfomycin	methicillin	none	{'e1': {'word': 'fosfomycin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d163.s0.e1'}, 'e2': {'word': 'methicillin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d163.s0.e2'}, 'sentence_id': 'DDI-MedLine.d163.s0'}	In vitro activity of DRUGUNRELATED combined with DRUG against clinical isolates of DRUGOTHER - resistant Staphylococcus aureus .
This study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant Staphylococcus aureus (MRSA). 	minocycline	fosfomycin	none	{'e1': {'word': 'minocycline', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d163.s1.e0'}, 'e2': {'word': 'fosfomycin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d163.s1.e1'}, 'sentence_id': 'DDI-MedLine.d163.s1'}	This study aimed to evaluate the in vitro activity of DRUG combined with DRUGOTHER against isolates of DRUGUNRELATED - resistant Staphylococcus aureus ( MRSA ) .
This study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant Staphylococcus aureus (MRSA). 	minocycline	methicillin	none	{'e1': {'word': 'minocycline', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d163.s1.e0'}, 'e2': {'word': 'methicillin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d163.s1.e2'}, 'sentence_id': 'DDI-MedLine.d163.s1'}	This study aimed to evaluate the in vitro activity of DRUG combined with DRUGUNRELATED against isolates of DRUGOTHER - resistant Staphylococcus aureus ( MRSA ) .
This study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant Staphylococcus aureus (MRSA). 	fosfomycin	methicillin	none	{'e1': {'word': 'fosfomycin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d163.s1.e1'}, 'e2': {'word': 'methicillin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d163.s1.e2'}, 'sentence_id': 'DDI-MedLine.d163.s1'}	This study aimed to evaluate the in vitro activity of DRUGUNRELATED combined with DRUG against isolates of DRUGOTHER - resistant Staphylococcus aureus ( MRSA ) .
The susceptibility results for minocycline and fosfomycin were interpreted according to the most relevant criteria. 	minocycline	fosfomycin	none	{'e1': {'word': 'minocycline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d163.s4.e0'}, 'e2': {'word': 'fosfomycin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d163.s4.e1'}, 'sentence_id': 'DDI-MedLine.d163.s4'}	The susceptibility results for DRUG and DRUGOTHER were interpreted according to the most relevant criteria .
The combination of minocycline and fosfomycin can be synergistic against MRSA. 	minocycline	fosfomycin	effect	{'e1': {'word': 'minocycline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d163.s7.e0'}, 'e2': {'word': 'fosfomycin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d163.s7.e1'}, 'sentence_id': 'DDI-MedLine.d163.s7'}	The combination of DRUG and DRUGOTHER can be synergistic against MRSA .
In the present study, we tested whether the highly specific metabotropic glutamate receptor 5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine, reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d161.s3.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d161.s3.e1'}, 'sentence_id': 'DDI-MedLine.d161.s3'}	In the present study , we tested whether the highly specific metabotropic glutamate receptor 5 antagonist , DRUG , reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of DRUGOTHER .
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d161.s4.e0'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d161.s4.e1'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	Weekly intramuscular DRUG injections ( 0.2 - 0.5 mg / kg body weight ) , in combination with daily administration of DRUGOTHER or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( DRUGUNRELATED / DRUGUNRELATED versus DRUGUNRELATED / vehicle ) .
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d161.s4.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d161.s4.e2'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	Weekly intramuscular DRUG injections ( 0.2 - 0.5 mg / kg body weight ) , in combination with daily administration of DRUGUNRELATED or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( DRUGOTHER / DRUGUNRELATED versus DRUGUNRELATED / vehicle ) .
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d161.s4.e0'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d161.s4.e3'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	Weekly intramuscular DRUG injections ( 0.2 - 0.5 mg / kg body weight ) , in combination with daily administration of DRUGUNRELATED or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( DRUGUNRELATED / DRUGOTHER versus DRUGUNRELATED / vehicle ) .
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d161.s4.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(46, 46)], 'id': 'DDI-MedLine.d161.s4.e4'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	Weekly intramuscular DRUG injections ( 0.2 - 0.5 mg / kg body weight ) , in combination with daily administration of DRUGUNRELATED or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( DRUGUNRELATED / DRUGUNRELATED versus DRUGOTHER / vehicle ) .
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d161.s4.e1'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d161.s4.e2'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	Weekly intramuscular DRUGUNRELATED injections ( 0.2 - 0.5 mg / kg body weight ) , in combination with daily administration of DRUG or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( DRUGOTHER / DRUGUNRELATED versus DRUGUNRELATED / vehicle ) .
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	none	{'e1': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d161.s4.e1'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d161.s4.e3'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	Weekly intramuscular DRUGUNRELATED injections ( 0.2 - 0.5 mg / kg body weight ) , in combination with daily administration of DRUG or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( DRUGUNRELATED / DRUGOTHER versus DRUGUNRELATED / vehicle ) .
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d161.s4.e1'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(46, 46)], 'id': 'DDI-MedLine.d161.s4.e4'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	Weekly intramuscular DRUGUNRELATED injections ( 0.2 - 0.5 mg / kg body weight ) , in combination with daily administration of DRUG or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( DRUGUNRELATED / DRUGUNRELATED versus DRUGOTHER / vehicle ) .
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d161.s4.e2'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d161.s4.e3'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	Weekly intramuscular DRUGUNRELATED injections ( 0.2 - 0.5 mg / kg body weight ) , in combination with daily administration of DRUGUNRELATED or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( DRUG / DRUGOTHER versus DRUGUNRELATED / vehicle ) .
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d161.s4.e2'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(46, 46)], 'id': 'DDI-MedLine.d161.s4.e4'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	Weekly intramuscular DRUGUNRELATED injections ( 0.2 - 0.5 mg / kg body weight ) , in combination with daily administration of DRUGUNRELATED or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( DRUG / DRUGUNRELATED versus DRUGOTHER / vehicle ) .
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d161.s4.e3'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(46, 46)], 'id': 'DDI-MedLine.d161.s4.e4'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	Weekly intramuscular DRUGUNRELATED injections ( 0.2 - 0.5 mg / kg body weight ) , in combination with daily administration of DRUGUNRELATED or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( DRUGUNRELATED / DRUG versus DRUGOTHER / vehicle ) .
After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d161.s5.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d161.s5.e1'}, 'sentence_id': 'DDI-MedLine.d161.s5'}	After 21 weeks of DRUG treatment , all DRUGOTHER / vehicle - treated animals displayed parkinsonian symptoms , whereas none of the DRUGUNRELATED / DRUGUNRELATED - treated monkeys were significantly affected .
After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d161.s5.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d161.s5.e2'}, 'sentence_id': 'DDI-MedLine.d161.s5'}	After 21 weeks of DRUG treatment , all DRUGUNRELATED / vehicle - treated animals displayed parkinsonian symptoms , whereas none of the DRUGOTHER / DRUGUNRELATED - treated monkeys were significantly affected .
After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d161.s5.e0'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d161.s5.e3'}, 'sentence_id': 'DDI-MedLine.d161.s5'}	After 21 weeks of DRUG treatment , all DRUGUNRELATED / vehicle - treated animals displayed parkinsonian symptoms , whereas none of the DRUGUNRELATED / DRUGOTHER - treated monkeys were significantly affected .
After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d161.s5.e1'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d161.s5.e2'}, 'sentence_id': 'DDI-MedLine.d161.s5'}	After 21 weeks of DRUGUNRELATED treatment , all DRUG / vehicle - treated animals displayed parkinsonian symptoms , whereas none of the DRUGOTHER / DRUGUNRELATED - treated monkeys were significantly affected .
After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d161.s5.e1'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d161.s5.e3'}, 'sentence_id': 'DDI-MedLine.d161.s5'}	After 21 weeks of DRUGUNRELATED treatment , all DRUG / vehicle - treated animals displayed parkinsonian symptoms , whereas none of the DRUGUNRELATED / DRUGOTHER - treated monkeys were significantly affected .
After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	effect	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d161.s5.e2'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d161.s5.e3'}, 'sentence_id': 'DDI-MedLine.d161.s5'}	After 21 weeks of DRUGUNRELATED treatment , all DRUGUNRELATED / vehicle - treated animals displayed parkinsonian symptoms , whereas none of the DRUG / DRUGOTHER - treated monkeys were significantly affected .
These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	effect	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(46, 46)], 'id': 'DDI-MedLine.d161.s6.e0'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(48, 48)], 'id': 'DDI-MedLine.d161.s6.e1'}, 'sentence_id': 'DDI-MedLine.d161.s6'}	These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data , and with post-mortem stereological counts of midbrain dopaminergic neurons , as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity , which were all significantly higher in DRUG / DRUGOTHER - treated animals than in DRUGUNRELATED / vehicle - treated monkeys .
These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(46, 46)], 'id': 'DDI-MedLine.d161.s6.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(54, 54)], 'id': 'DDI-MedLine.d161.s6.e2'}, 'sentence_id': 'DDI-MedLine.d161.s6'}	These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data , and with post-mortem stereological counts of midbrain dopaminergic neurons , as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity , which were all significantly higher in DRUG / DRUGUNRELATED - treated animals than in DRUGOTHER / vehicle - treated monkeys .
These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(48, 48)], 'id': 'DDI-MedLine.d161.s6.e1'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(54, 54)], 'id': 'DDI-MedLine.d161.s6.e2'}, 'sentence_id': 'DDI-MedLine.d161.s6'}	These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data , and with post-mortem stereological counts of midbrain dopaminergic neurons , as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity , which were all significantly higher in DRUGUNRELATED / DRUG - treated animals than in DRUGOTHER / vehicle - treated monkeys .
The 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine treatment also had a significant effect on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced loss of norepinephrine neurons in the locus coeruleus and adjoining A5 and A7 noradrenaline cell groups. 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	effect	{'e1': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d161.s7.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d161.s7.e1'}, 'sentence_id': 'DDI-MedLine.d161.s7'}	The DRUG treatment also had a significant effect on the DRUGOTHER - induced loss of norepinephrine neurons in the locus coeruleus and adjoining A5 and A7 noradrenaline cell groups .
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d161.s8.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d161.s8.e1'}, 'sentence_id': 'DDI-MedLine.d161.s8'}	In DRUG / vehicle - treated animals , almost 40 % loss of tyrosine hydroxylase - positive norepinephrine neurons was found in locus coeruleus / A5 / A7 noradrenaline cell groups , whereas the extent of neuronal loss was lower than 15 % of control values in DRUGOTHER / DRUGUNRELATED - treated monkeys .
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d161.s8.e0'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(49, 49)], 'id': 'DDI-MedLine.d161.s8.e2'}, 'sentence_id': 'DDI-MedLine.d161.s8'}	In DRUG / vehicle - treated animals , almost 40 % loss of tyrosine hydroxylase - positive norepinephrine neurons was found in locus coeruleus / A5 / A7 noradrenaline cell groups , whereas the extent of neuronal loss was lower than 15 % of control values in DRUGUNRELATED / DRUGOTHER - treated monkeys .
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	effect	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d161.s8.e1'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(49, 49)], 'id': 'DDI-MedLine.d161.s8.e2'}, 'sentence_id': 'DDI-MedLine.d161.s8'}	In DRUGUNRELATED / vehicle - treated animals , almost 40 % loss of tyrosine hydroxylase - positive norepinephrine neurons was found in locus coeruleus / A5 / A7 noradrenaline cell groups , whereas the extent of neuronal loss was lower than 15 % of control values in DRUG / DRUGOTHER - treated monkeys .
Our data demonstrate that chronic treatment with the metabotropic glutamate receptor 5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine, significantly reduces 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity towards dopaminergic and noradrenergic cell groups in non-human primates. 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	effect	{'e1': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d161.s9.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d161.s9.e1'}, 'sentence_id': 'DDI-MedLine.d161.s9'}	Our data demonstrate that chronic treatment with the metabotropic glutamate receptor 5 antagonist , DRUG , significantly reduces DRUGOTHER toxicity towards dopaminergic and noradrenergic cell groups in non-human primates .
To determine whether the co-injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of adeno-associated virus-2 (AAV2).	adeno-associated virus-2	AAV2	none	{'e1': {'word': 'adeno-associated virus-2', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d190.s1.e0'}, 'e2': {'word': 'AAV2', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d190.s1.e1'}, 'sentence_id': 'DDI-MedLine.d190.s1'}	To determine whether the co-injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of DRUG ( DRUGOTHER ) .
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	AAV2	collagenase	none	{'e1': {'word': 'AAV2', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d190.s2.e0'}, 'e2': {'word': 'collagenase', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d190.s2.e1'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	DRUG containing cDNA encoding enhanced green fluorescent protein ( GFP ) , under the control of a chicken - actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED , or DRUGUNRELATED .
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	AAV2	hyaluronan lyase	none	{'e1': {'word': 'AAV2', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d190.s2.e0'}, 'e2': {'word': 'hyaluronan lyase', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d190.s2.e2'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	DRUG containing cDNA encoding enhanced green fluorescent protein ( GFP ) , under the control of a chicken - actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED , or DRUGUNRELATED .
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	AAV2	heparinase III	none	{'e1': {'word': 'AAV2', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d190.s2.e0'}, 'e2': {'word': 'heparinase III', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d190.s2.e3'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	DRUG containing cDNA encoding enhanced green fluorescent protein ( GFP ) , under the control of a chicken - actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER , or DRUGUNRELATED .
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	AAV2	chondroitin ABC lyase	none	{'e1': {'word': 'AAV2', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d190.s2.e0'}, 'e2': {'word': 'chondroitin ABC lyase', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d190.s2.e4'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	DRUG containing cDNA encoding enhanced green fluorescent protein ( GFP ) , under the control of a chicken - actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED , or DRUGOTHER .
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	collagenase	hyaluronan lyase	none	{'e1': {'word': 'collagenase', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d190.s2.e1'}, 'e2': {'word': 'hyaluronan lyase', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d190.s2.e2'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	DRUGUNRELATED containing cDNA encoding enhanced green fluorescent protein ( GFP ) , under the control of a chicken - actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including DRUG , DRUGOTHER , DRUGUNRELATED , or DRUGUNRELATED .
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	collagenase	heparinase III	none	{'e1': {'word': 'collagenase', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d190.s2.e1'}, 'e2': {'word': 'heparinase III', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d190.s2.e3'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	DRUGUNRELATED containing cDNA encoding enhanced green fluorescent protein ( GFP ) , under the control of a chicken - actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including DRUG , DRUGUNRELATED , DRUGOTHER , or DRUGUNRELATED .
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	collagenase	chondroitin ABC lyase	none	{'e1': {'word': 'collagenase', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d190.s2.e1'}, 'e2': {'word': 'chondroitin ABC lyase', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d190.s2.e4'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	DRUGUNRELATED containing cDNA encoding enhanced green fluorescent protein ( GFP ) , under the control of a chicken - actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including DRUG , DRUGUNRELATED , DRUGUNRELATED , or DRUGOTHER .
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	hyaluronan lyase	heparinase III	none	{'e1': {'word': 'hyaluronan lyase', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d190.s2.e2'}, 'e2': {'word': 'heparinase III', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d190.s2.e3'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	DRUGUNRELATED containing cDNA encoding enhanced green fluorescent protein ( GFP ) , under the control of a chicken - actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including DRUGUNRELATED , DRUG , DRUGOTHER , or DRUGUNRELATED .
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	hyaluronan lyase	chondroitin ABC lyase	none	{'e1': {'word': 'hyaluronan lyase', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d190.s2.e2'}, 'e2': {'word': 'chondroitin ABC lyase', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d190.s2.e4'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	DRUGUNRELATED containing cDNA encoding enhanced green fluorescent protein ( GFP ) , under the control of a chicken - actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including DRUGUNRELATED , DRUG , DRUGUNRELATED , or DRUGOTHER .
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	heparinase III	chondroitin ABC lyase	none	{'e1': {'word': 'heparinase III', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d190.s2.e3'}, 'e2': {'word': 'chondroitin ABC lyase', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d190.s2.e4'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	DRUGUNRELATED containing cDNA encoding enhanced green fluorescent protein ( GFP ) , under the control of a chicken - actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including DRUGUNRELATED , DRUGUNRELATED , DRUG , or DRUGOTHER .
The addition of heparinase III or chondroitin ABC lyase greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina. 	heparinase III	chondroitin ABC lyase	none	{'e1': {'word': 'heparinase III', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d190.s5.e0'}, 'e2': {'word': 'chondroitin ABC lyase', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d190.s5.e1'}, 'sentence_id': 'DDI-MedLine.d190.s5'}	The addition of DRUG or DRUGOTHER greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina .
Hyaluronan lyase had a limited effect and collagenase was ineffective. 	Hyaluronan lyase	collagenase	none	{'e1': {'word': 'Hyaluronan lyase', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d190.s6.e0'}, 'e2': {'word': 'collagenase', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d190.s6.e1'}, 'sentence_id': 'DDI-MedLine.d190.s6'}	DRUG had a limited effect and DRUGOTHER was ineffective .
Electroretinograms survived with higher concentrations of heparinase III and chondroitin ABC lyase than were required for optimal retinal transduction. 	heparinase III	chondroitin ABC lyase	none	{'e1': {'word': 'heparinase III', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d190.s7.e0'}, 'e2': {'word': 'chondroitin ABC lyase', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d190.s7.e1'}, 'sentence_id': 'DDI-MedLine.d190.s7'}	Electroretinograms survived with higher concentrations of DRUG and DRUGOTHER than were required for optimal retinal transduction .
AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. 	AAV2	heparinase III	effect	{'e1': {'word': 'AAV2', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d190.s8.e0'}, 'e2': {'word': 'heparinase III', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d190.s8.e1'}, 'sentence_id': 'DDI-MedLine.d190.s8'}	DRUG - mediated retinal transduction is improved by co-injection of DRUGOTHER or DRUGUNRELATED .
AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. 	AAV2	chondroitin ABC lyase	effect	{'e1': {'word': 'AAV2', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d190.s8.e0'}, 'e2': {'word': 'chondroitin ABC lyase', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d190.s8.e2'}, 'sentence_id': 'DDI-MedLine.d190.s8'}	DRUG - mediated retinal transduction is improved by co-injection of DRUGUNRELATED or DRUGOTHER .
AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. 	heparinase III	chondroitin ABC lyase	none	{'e1': {'word': 'heparinase III', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d190.s8.e1'}, 'e2': {'word': 'chondroitin ABC lyase', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d190.s8.e2'}, 'sentence_id': 'DDI-MedLine.d190.s8'}	DRUGUNRELATED - mediated retinal transduction is improved by co-injection of DRUG or DRUGOTHER .
Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.	Implanon	antiretroviral	effect	{'e1': {'word': 'Implanon', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d208.s0.e0'}, 'e2': {'word': 'antiretroviral', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d208.s0.e1'}, 'sentence_id': 'DDI-MedLine.d208.s0'}	DRUG failure in an HIV - positive woman on DRUGOTHER therapy resulting in two ectopic pregnancies .
We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.	antiretroviral	Implanon	effect	{'e1': {'word': 'antiretroviral', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d208.s3.e0'}, 'e2': {'word': 'Implanon', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d208.s3.e1'}, 'sentence_id': 'DDI-MedLine.d208.s3'}	We present an interesting case of an HIV - positive woman on DRUG therapy having tubal pregnancies on two separate occasions with DRUGOTHER in place .
"[Influence of hemantane and doxycycline on MPTP-evoked behavior violations in C57BL/6 mice].
"	hemantane	doxycycline	none	{'e1': {'word': 'hemantane', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d214.s0.e0'}, 'e2': {'word': 'doxycycline', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d214.s0.e1'}, 'sentence_id': 'DDI-MedLine.d214.s0'}	[ Influence of DRUG and DRUGOTHER on MPTP - evoked behavior violations in C57BL / 6 mice ] .
The effects of anti-parkinsonian drug hemantane [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) 	anti-parkinsonian drug	hemantane	none	{'e1': {'word': 'anti-parkinsonian drug', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d214.s1.e0'}, 'e2': {'word': 'hemantane', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d214.s1.e1'}, 'sentence_id': 'DDI-MedLine.d214.s1'}	The effects of DRUG DRUGOTHER [ DRUGUNRELATED ] ( 10 mg / kg , p. o. )
The effects of anti-parkinsonian drug hemantane [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) 	anti-parkinsonian drug	(2-adamantyl)hexamethylenimine	none	{'e1': {'word': 'anti-parkinsonian drug', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d214.s1.e0'}, 'e2': {'word': '(2-adamantyl)hexamethylenimine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d214.s1.e2'}, 'sentence_id': 'DDI-MedLine.d214.s1'}	The effects of DRUG DRUGUNRELATED [ DRUGOTHER ] ( 10 mg / kg , p. o. )
The effects of anti-parkinsonian drug hemantane [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) 	hemantane	(2-adamantyl)hexamethylenimine	none	{'e1': {'word': 'hemantane', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d214.s1.e1'}, 'e2': {'word': '(2-adamantyl)hexamethylenimine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d214.s1.e2'}, 'sentence_id': 'DDI-MedLine.d214.s1'}	The effects of DRUGUNRELATED DRUG [ DRUGOTHER ] ( 10 mg / kg , p. o. )
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) 	antibiotic drug	doxycycline	none	{'e1': {'word': 'antibiotic drug', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d214.s2.e0'}, 'e2': {'word': 'doxycycline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d214.s2.e1'}, 'sentence_id': 'DDI-MedLine.d214.s2'}	and / or DRUG DRUGOTHER ( 100 mg / kg , p. o. ) , as well as that of neurotoxin DRUGUNRELATED ( DRUGUNRELATED ) ( 4 x 20 mg / kg , i. p. )
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) 	antibiotic drug	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine	none	{'e1': {'word': 'antibiotic drug', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d214.s2.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d214.s2.e2'}, 'sentence_id': 'DDI-MedLine.d214.s2'}	and / or DRUG DRUGUNRELATED ( 100 mg / kg , p. o. ) , as well as that of neurotoxin DRUGOTHER ( DRUGUNRELATED ) ( 4 x 20 mg / kg , i. p. )
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) 	antibiotic drug	MPTP	none	{'e1': {'word': 'antibiotic drug', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d214.s2.e0'}, 'e2': {'word': 'MPTP', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d214.s2.e3'}, 'sentence_id': 'DDI-MedLine.d214.s2'}	and / or DRUG DRUGUNRELATED ( 100 mg / kg , p. o. ) , as well as that of neurotoxin DRUGUNRELATED ( DRUGOTHER ) ( 4 x 20 mg / kg , i. p. )
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) 	doxycycline	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine	none	{'e1': {'word': 'doxycycline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d214.s2.e1'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d214.s2.e2'}, 'sentence_id': 'DDI-MedLine.d214.s2'}	and / or DRUGUNRELATED DRUG ( 100 mg / kg , p. o. ) , as well as that of neurotoxin DRUGOTHER ( DRUGUNRELATED ) ( 4 x 20 mg / kg , i. p. )
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) 	doxycycline	MPTP	none	{'e1': {'word': 'doxycycline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d214.s2.e1'}, 'e2': {'word': 'MPTP', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d214.s2.e3'}, 'sentence_id': 'DDI-MedLine.d214.s2'}	and / or DRUGUNRELATED DRUG ( 100 mg / kg , p. o. ) , as well as that of neurotoxin DRUGUNRELATED ( DRUGOTHER ) ( 4 x 20 mg / kg , i. p. )
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) 	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine	MPTP	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d214.s2.e2'}, 'e2': {'word': 'MPTP', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d214.s2.e3'}, 'sentence_id': 'DDI-MedLine.d214.s2'}	and / or DRUGUNRELATED DRUGUNRELATED ( 100 mg / kg , p. o. ) , as well as that of neurotoxin DRUG ( DRUGOTHER ) ( 4 x 20 mg / kg , i. p. )
Acute administration of hemantane or doxycycline failed to influence locomotion in mice, while their combination normalized motor activity. 	hemantane	doxycycline	effect	{'e1': {'word': 'hemantane', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d214.s5.e0'}, 'e2': {'word': 'doxycycline', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d214.s5.e1'}, 'sentence_id': 'DDI-MedLine.d214.s5'}	Acute administration of DRUG or DRUGOTHER failed to influence locomotion in mice , while their combination normalized motor activity .
"Interaction of dacarbazine and imexon, in vitro and in vivo, in human A375 melanoma cells.
"	dacarbazine	imexon	none	{'e1': {'word': 'dacarbazine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d147.s0.e0'}, 'e2': {'word': 'imexon', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d147.s0.e1'}, 'sentence_id': 'DDI-MedLine.d147.s0'}	Interaction of DRUG and DRUGOTHER , in vitro and in vivo , in human A375 melanoma cells .
We evaluated mechanisms of interaction between the alkyating agent dacarbazine (DTIC) and the pro-oxidant, imexon, in the human A375 melanoma cell line.	dacarbazine	DTIC	none	{'e1': {'word': 'dacarbazine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d147.s1.e0'}, 'e2': {'word': 'DTIC', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d147.s1.e1'}, 'sentence_id': 'DDI-MedLine.d147.s1'}	We evaluated mechanisms of interaction between the alkyating agent DRUG ( DRUGOTHER ) and the pro-oxidant , DRUGUNRELATED , in the human A375 melanoma cell line .
We evaluated mechanisms of interaction between the alkyating agent dacarbazine (DTIC) and the pro-oxidant, imexon, in the human A375 melanoma cell line.	dacarbazine	imexon	none	{'e1': {'word': 'dacarbazine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d147.s1.e0'}, 'e2': {'word': 'imexon', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d147.s1.e2'}, 'sentence_id': 'DDI-MedLine.d147.s1'}	We evaluated mechanisms of interaction between the alkyating agent DRUG ( DRUGUNRELATED ) and the pro-oxidant , DRUGOTHER , in the human A375 melanoma cell line .
We evaluated mechanisms of interaction between the alkyating agent dacarbazine (DTIC) and the pro-oxidant, imexon, in the human A375 melanoma cell line.	DTIC	imexon	none	{'e1': {'word': 'DTIC', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d147.s1.e1'}, 'e2': {'word': 'imexon', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d147.s1.e2'}, 'sentence_id': 'DDI-MedLine.d147.s1'}	We evaluated mechanisms of interaction between the alkyating agent DRUGUNRELATED ( DRUG ) and the pro-oxidant , DRUGOTHER , in the human A375 melanoma cell line .
The effect of DTIC and imexon, alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled drug uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay). 	DTIC	imexon	none	{'e1': {'word': 'DTIC', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d147.s2.e0'}, 'e2': {'word': 'imexon', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d147.s2.e1'}, 'sentence_id': 'DDI-MedLine.d147.s2'}	The effect of DRUG and DRUGOTHER , alone and in combination , was evaluated for growth inhibition ( MTT ) , radiolabeled drug uptake , cellular thiol content ( HPLC ) , and DNA strand breaks ( Comet assay ) .
There was a >75% reduction in cellular glutathione and cysteine with imexon but not DTIC. 	imexon	DTIC	none	{'e1': {'word': 'imexon', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d147.s6.e0'}, 'e2': {'word': 'DTIC', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d147.s6.e1'}, 'sentence_id': 'DDI-MedLine.d147.s6'}	There was a > 75 % reduction in cellular glutathione and cysteine with DRUG but not DRUGOTHER .
Imexon and dacarbazine show additive effects in vitro but not in vivo in human A375 melanoma cells.	Imexon	dacarbazine	effect	{'e1': {'word': 'Imexon', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d147.s8.e0'}, 'e2': {'word': 'dacarbazine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d147.s8.e1'}, 'sentence_id': 'DDI-MedLine.d147.s8'}	DRUG and DRUGOTHER show additive effects in vitro but not in vivo in human A375 melanoma cells .
The authors report the case of an infant with confirmed congenital hypothyroidism on levothyroxine who experienced a possible drug interaction with simeticone. 	levothyroxine	simeticone	int	{'e1': {'word': 'levothyroxine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d181.s4.e0'}, 'e2': {'word': 'simeticone', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d181.s4.e1'}, 'sentence_id': 'DDI-MedLine.d181.s4'}	The authors report the case of an infant with confirmed congenital hypothyroidism on DRUG who experienced a possible drug interaction with DRUGOTHER .
Questioning revealed the child was taking Infacol drops before feeds while on levothyroxine. 	Infacol	levothyroxine	none	{'e1': {'word': 'Infacol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d181.s6.e0'}, 'e2': {'word': 'levothyroxine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d181.s6.e1'}, 'sentence_id': 'DDI-MedLine.d181.s6'}	Questioning revealed the child was taking DRUG drops before feeds while on DRUGOTHER .
Drug interaction of thyroxine with simeticone has not been reported previously and is not listed in the British National Formulary for Children. 	thyroxine	simeticone	none	{'e1': {'word': 'thyroxine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d181.s8.e0'}, 'e2': {'word': 'simeticone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d181.s8.e1'}, 'sentence_id': 'DDI-MedLine.d181.s8'}	Drug interaction of DRUG with DRUGOTHER has not been reported previously and is not listed in the British National Formulary for Children .
The aim of the present study was to investigate whether HB-EGF is a therapeutic target for T-ALL, and to further elucidate the antitumor effects of a specific inhibitor of HB-EGF, cross-reacting material 197 (CRM197). 	cross-reacting material 197	CRM197	none	{'e1': {'word': 'cross-reacting material 197', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d201.s4.e0'}, 'e2': {'word': 'CRM197', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d201.s4.e1'}, 'sentence_id': 'DDI-MedLine.d201.s4'}	The aim of the present study was to investigate whether HB - EGF is a therapeutic target for T - ALL , and to further elucidate the antitumor effects of a specific inhibitor of HB - EGF , DRUG ( DRUGOTHER ) .
We elucidated the expression of HB-EGF in T-ALL cell lines, and evaluated the effect of CRM197 on these cells alone or in combination with anticancer agent. 	CRM197	anticancer agent	none	{'e1': {'word': 'CRM197', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d201.s5.e0'}, 'e2': {'word': 'anticancer agent', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d201.s5.e1'}, 'sentence_id': 'DDI-MedLine.d201.s5'}	We elucidated the expression of HB - EGF in T - ALL cell lines , and evaluated the effect of DRUG on these cells alone or in combination with DRUGOTHER .
CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. 	CRM197	CRM197	none	{'e1': {'word': 'CRM197', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d201.s9.e0'}, 'e2': {'word': 'CRM197', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d201.s9.e1'}, 'sentence_id': 'DDI-MedLine.d201.s9'}	DRUG induced apoptosis , and furthermore , the combination of DRUGOTHER plus DRUGUNRELATED enhanced cytotoxicity in a T - ALL cell line .
CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. 	CRM197	doxorubicin	none	{'e1': {'word': 'CRM197', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d201.s9.e0'}, 'e2': {'word': 'doxorubicin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d201.s9.e2'}, 'sentence_id': 'DDI-MedLine.d201.s9'}	DRUG induced apoptosis , and furthermore , the combination of DRUGUNRELATED plus DRUGOTHER enhanced cytotoxicity in a T - ALL cell line .
CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. 	CRM197	doxorubicin	effect	{'e1': {'word': 'CRM197', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d201.s9.e1'}, 'e2': {'word': 'doxorubicin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d201.s9.e2'}, 'sentence_id': 'DDI-MedLine.d201.s9'}	DRUGUNRELATED induced apoptosis , and furthermore , the combination of DRUG plus DRUGOTHER enhanced cytotoxicity in a T - ALL cell line .
"Amphetamine locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with quinpirole.
"	Amphetamine	quinpirole	none	{'e1': {'word': 'Amphetamine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d184.s0.e0'}, 'e2': {'word': 'quinpirole', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d184.s0.e1'}, 'sentence_id': 'DDI-MedLine.d184.s0'}	DRUG locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with DRUGOTHER .
The objective was to analyze the effects of neonatal quinpirole treatment on effects of amphetamine in adolescent rats using locomotor sensitization and conditioned place preference procedures. 	quinpirole	amphetamine	none	{'e1': {'word': 'quinpirole', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d184.s2.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d184.s2.e1'}, 'sentence_id': 'DDI-MedLine.d184.s2'}	The objective was to analyze the effects of neonatal DRUG treatment on effects of DRUGOTHER in adolescent rats using locomotor sensitization and conditioned place preference procedures .
In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. 	quinpirole	amphetamine	effect	{'e1': {'word': 'quinpirole', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d184.s5.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d184.s5.e1'}, 'sentence_id': 'DDI-MedLine.d184.s5'}	In female rats , neonatal DRUG treatment enhanced DRUGOTHER locomotor sensitization compared with DRUGUNRELATED - free controls sensitized to DRUGUNRELATED .
In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. 	quinpirole	quinpirole	none	{'e1': {'word': 'quinpirole', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d184.s5.e0'}, 'e2': {'word': 'quinpirole', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d184.s5.e2'}, 'sentence_id': 'DDI-MedLine.d184.s5'}	In female rats , neonatal DRUG treatment enhanced DRUGUNRELATED locomotor sensitization compared with DRUGOTHER - free controls sensitized to DRUGUNRELATED .
In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. 	quinpirole	amphetamine	none	{'e1': {'word': 'quinpirole', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d184.s5.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d184.s5.e3'}, 'sentence_id': 'DDI-MedLine.d184.s5'}	In female rats , neonatal DRUG treatment enhanced DRUGUNRELATED locomotor sensitization compared with DRUGUNRELATED - free controls sensitized to DRUGOTHER .
In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. 	amphetamine	quinpirole	none	{'e1': {'word': 'amphetamine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d184.s5.e1'}, 'e2': {'word': 'quinpirole', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d184.s5.e2'}, 'sentence_id': 'DDI-MedLine.d184.s5'}	In female rats , neonatal DRUGUNRELATED treatment enhanced DRUG locomotor sensitization compared with DRUGOTHER - free controls sensitized to DRUGUNRELATED .
In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. 	amphetamine	amphetamine	none	{'e1': {'word': 'amphetamine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d184.s5.e1'}, 'e2': {'word': 'amphetamine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d184.s5.e3'}, 'sentence_id': 'DDI-MedLine.d184.s5'}	In female rats , neonatal DRUGUNRELATED treatment enhanced DRUG locomotor sensitization compared with DRUGUNRELATED - free controls sensitized to DRUGOTHER .
In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. 	quinpirole	amphetamine	none	{'e1': {'word': 'quinpirole', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d184.s5.e2'}, 'e2': {'word': 'amphetamine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d184.s5.e3'}, 'sentence_id': 'DDI-MedLine.d184.s5'}	In female rats , neonatal DRUGUNRELATED treatment enhanced DRUGUNRELATED locomotor sensitization compared with DRUG - free controls sensitized to DRUGOTHER .
Male rats demonstrated sensitization to amphetamine, although this was muted compared with female rats, and were unaffected by neonatal quinpirole. 	amphetamine	quinpirole	none	{'e1': {'word': 'amphetamine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d184.s6.e0'}, 'e2': {'word': 'quinpirole', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d184.s6.e1'}, 'sentence_id': 'DDI-MedLine.d184.s6'}	Male rats demonstrated sensitization to DRUG , although this was muted compared with female rats , and were unaffected by neonatal DRUGOTHER .
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	quinpirole	amphetamine	none	{'e1': {'word': 'quinpirole', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d184.s8.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d184.s8.e1'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	Rats treated with neonatal DRUG enhanced time spent in the DRUGOTHER - paired context compared with DRUGUNRELATED - free controls conditioned with DRUGUNRELATED , but only female controls conditioned with DRUGUNRELATED spent more time in the drug - paired context compared with saline - treated controls .
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	quinpirole	quinpirole	none	{'e1': {'word': 'quinpirole', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d184.s8.e0'}, 'e2': {'word': 'quinpirole', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d184.s8.e2'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	Rats treated with neonatal DRUG enhanced time spent in the DRUGUNRELATED - paired context compared with DRUGOTHER - free controls conditioned with DRUGUNRELATED , but only female controls conditioned with DRUGUNRELATED spent more time in the drug - paired context compared with saline - treated controls .
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	quinpirole	amphetamine	none	{'e1': {'word': 'quinpirole', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d184.s8.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d184.s8.e3'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	Rats treated with neonatal DRUG enhanced time spent in the DRUGUNRELATED - paired context compared with DRUGUNRELATED - free controls conditioned with DRUGOTHER , but only female controls conditioned with DRUGUNRELATED spent more time in the drug - paired context compared with saline - treated controls .
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	quinpirole	amphetamine	none	{'e1': {'word': 'quinpirole', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d184.s8.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d184.s8.e4'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	Rats treated with neonatal DRUG enhanced time spent in the DRUGUNRELATED - paired context compared with DRUGUNRELATED - free controls conditioned with DRUGUNRELATED , but only female controls conditioned with DRUGOTHER spent more time in the drug - paired context compared with saline - treated controls .
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	amphetamine	quinpirole	none	{'e1': {'word': 'amphetamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d184.s8.e1'}, 'e2': {'word': 'quinpirole', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d184.s8.e2'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	Rats treated with neonatal DRUGUNRELATED enhanced time spent in the DRUG - paired context compared with DRUGOTHER - free controls conditioned with DRUGUNRELATED , but only female controls conditioned with DRUGUNRELATED spent more time in the drug - paired context compared with saline - treated controls .
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	amphetamine	amphetamine	none	{'e1': {'word': 'amphetamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d184.s8.e1'}, 'e2': {'word': 'amphetamine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d184.s8.e3'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	Rats treated with neonatal DRUGUNRELATED enhanced time spent in the DRUG - paired context compared with DRUGUNRELATED - free controls conditioned with DRUGOTHER , but only female controls conditioned with DRUGUNRELATED spent more time in the drug - paired context compared with saline - treated controls .
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	amphetamine	amphetamine	none	{'e1': {'word': 'amphetamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d184.s8.e1'}, 'e2': {'word': 'amphetamine', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d184.s8.e4'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	Rats treated with neonatal DRUGUNRELATED enhanced time spent in the DRUG - paired context compared with DRUGUNRELATED - free controls conditioned with DRUGUNRELATED , but only female controls conditioned with DRUGOTHER spent more time in the drug - paired context compared with saline - treated controls .
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	quinpirole	amphetamine	none	{'e1': {'word': 'quinpirole', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d184.s8.e2'}, 'e2': {'word': 'amphetamine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d184.s8.e3'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	Rats treated with neonatal DRUGUNRELATED enhanced time spent in the DRUGUNRELATED - paired context compared with DRUG - free controls conditioned with DRUGOTHER , but only female controls conditioned with DRUGUNRELATED spent more time in the drug - paired context compared with saline - treated controls .
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	quinpirole	amphetamine	none	{'e1': {'word': 'quinpirole', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d184.s8.e2'}, 'e2': {'word': 'amphetamine', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d184.s8.e4'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	Rats treated with neonatal DRUGUNRELATED enhanced time spent in the DRUGUNRELATED - paired context compared with DRUG - free controls conditioned with DRUGUNRELATED , but only female controls conditioned with DRUGOTHER spent more time in the drug - paired context compared with saline - treated controls .
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	amphetamine	amphetamine	none	{'e1': {'word': 'amphetamine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d184.s8.e3'}, 'e2': {'word': 'amphetamine', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d184.s8.e4'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	Rats treated with neonatal DRUGUNRELATED enhanced time spent in the DRUGUNRELATED - paired context compared with DRUGUNRELATED - free controls conditioned with DRUG , but only female controls conditioned with DRUGOTHER spent more time in the drug - paired context compared with saline - treated controls .
"Interaction study of moxifloxacin and lomefloxacin with co-administered drugs.
"	moxifloxacin	lomefloxacin	none	{'e1': {'word': 'moxifloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d231.s0.e0'}, 'e2': {'word': 'lomefloxacin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d231.s0.e1'}, 'sentence_id': 'DDI-MedLine.d231.s0'}	Interaction study of DRUG and DRUGOTHER with co-administered drugs .
Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections. 	Moxifloxacin	lomefloxacin	none	{'e1': {'word': 'Moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s1.e0'}, 'e2': {'word': 'lomefloxacin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d231.s1.e1'}, 'sentence_id': 'DDI-MedLine.d231.s1'}	DRUG and DRUGOTHER are DRUGUNRELATED used in treating urinary and respiratory tract infections .
Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections. 	Moxifloxacin	fluoroquinolone antibiotics	none	{'e1': {'word': 'Moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s1.e0'}, 'e2': {'word': 'fluoroquinolone antibiotics', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d231.s1.e2'}, 'sentence_id': 'DDI-MedLine.d231.s1'}	DRUG and DRUGUNRELATED are DRUGOTHER used in treating urinary and respiratory tract infections .
Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections. 	lomefloxacin	fluoroquinolone antibiotics	none	{'e1': {'word': 'lomefloxacin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d231.s1.e1'}, 'e2': {'word': 'fluoroquinolone antibiotics', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d231.s1.e2'}, 'sentence_id': 'DDI-MedLine.d231.s1'}	DRUGUNRELATED and DRUG are DRUGOTHER used in treating urinary and respiratory tract infections .
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	moxifloxacin	fluoroquinolones	none	{'e1': {'word': 'moxifloxacin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d231.s3.e0'}, 'e2': {'word': 'fluoroquinolones', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d231.s3.e1'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	Being DRUG and lomefloxacin DRUGOTHER the interaction study of was carried out with DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED and DRUGUNRELATED .
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	moxifloxacin	sucralfate	none	{'e1': {'word': 'moxifloxacin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d231.s3.e0'}, 'e2': {'word': 'sucralfate', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d231.s3.e2'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	Being DRUG and lomefloxacin DRUGUNRELATED the interaction study of was carried out with DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED and DRUGUNRELATED .
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	moxifloxacin	gelusil	none	{'e1': {'word': 'moxifloxacin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d231.s3.e0'}, 'e2': {'word': 'gelusil', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d231.s3.e3'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	Being DRUG and lomefloxacin DRUGUNRELATED the interaction study of was carried out with DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED and DRUGUNRELATED .
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	moxifloxacin	erythromycin	none	{'e1': {'word': 'moxifloxacin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d231.s3.e0'}, 'e2': {'word': 'erythromycin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d231.s3.e4'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	Being DRUG and lomefloxacin DRUGUNRELATED the interaction study of was carried out with DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER and DRUGUNRELATED .
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	moxifloxacin	multi minerals	none	{'e1': {'word': 'moxifloxacin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d231.s3.e0'}, 'e2': {'word': 'multi minerals', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d231.s3.e5'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	Being DRUG and lomefloxacin DRUGUNRELATED the interaction study of was carried out with DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED and DRUGOTHER .
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	fluoroquinolones	sucralfate	none	{'e1': {'word': 'fluoroquinolones', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d231.s3.e1'}, 'e2': {'word': 'sucralfate', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d231.s3.e2'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	Being DRUGUNRELATED and lomefloxacin DRUG the interaction study of was carried out with DRUGOTHER , DRUGUNRELATED , DRUGUNRELATED and DRUGUNRELATED .
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	fluoroquinolones	gelusil	none	{'e1': {'word': 'fluoroquinolones', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d231.s3.e1'}, 'e2': {'word': 'gelusil', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d231.s3.e3'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	Being DRUGUNRELATED and lomefloxacin DRUG the interaction study of was carried out with DRUGUNRELATED , DRUGOTHER , DRUGUNRELATED and DRUGUNRELATED .
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	fluoroquinolones	erythromycin	none	{'e1': {'word': 'fluoroquinolones', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d231.s3.e1'}, 'e2': {'word': 'erythromycin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d231.s3.e4'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	Being DRUGUNRELATED and lomefloxacin DRUG the interaction study of was carried out with DRUGUNRELATED , DRUGUNRELATED , DRUGOTHER and DRUGUNRELATED .
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	fluoroquinolones	multi minerals	none	{'e1': {'word': 'fluoroquinolones', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d231.s3.e1'}, 'e2': {'word': 'multi minerals', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d231.s3.e5'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	Being DRUGUNRELATED and lomefloxacin DRUG the interaction study of was carried out with DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED and DRUGOTHER .
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	sucralfate	gelusil	none	{'e1': {'word': 'sucralfate', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d231.s3.e2'}, 'e2': {'word': 'gelusil', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d231.s3.e3'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	Being DRUGUNRELATED and lomefloxacin DRUGUNRELATED the interaction study of was carried out with DRUG , DRUGOTHER , DRUGUNRELATED and DRUGUNRELATED .
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	sucralfate	erythromycin	none	{'e1': {'word': 'sucralfate', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d231.s3.e2'}, 'e2': {'word': 'erythromycin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d231.s3.e4'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	Being DRUGUNRELATED and lomefloxacin DRUGUNRELATED the interaction study of was carried out with DRUG , DRUGUNRELATED , DRUGOTHER and DRUGUNRELATED .
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	sucralfate	multi minerals	none	{'e1': {'word': 'sucralfate', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d231.s3.e2'}, 'e2': {'word': 'multi minerals', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d231.s3.e5'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	Being DRUGUNRELATED and lomefloxacin DRUGUNRELATED the interaction study of was carried out with DRUG , DRUGUNRELATED , DRUGUNRELATED and DRUGOTHER .
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	gelusil	erythromycin	none	{'e1': {'word': 'gelusil', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d231.s3.e3'}, 'e2': {'word': 'erythromycin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d231.s3.e4'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	Being DRUGUNRELATED and lomefloxacin DRUGUNRELATED the interaction study of was carried out with DRUGUNRELATED , DRUG , DRUGOTHER and DRUGUNRELATED .
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	gelusil	multi minerals	none	{'e1': {'word': 'gelusil', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d231.s3.e3'}, 'e2': {'word': 'multi minerals', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d231.s3.e5'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	Being DRUGUNRELATED and lomefloxacin DRUGUNRELATED the interaction study of was carried out with DRUGUNRELATED , DRUG , DRUGUNRELATED and DRUGOTHER .
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	erythromycin	multi minerals	none	{'e1': {'word': 'erythromycin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d231.s3.e4'}, 'e2': {'word': 'multi minerals', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d231.s3.e5'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	Being DRUGUNRELATED and lomefloxacin DRUGUNRELATED the interaction study of was carried out with DRUGUNRELATED , DRUGUNRELATED , DRUG and DRUGOTHER .
The response of moxifloxacin and lomefloxacin after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector. 	moxifloxacin	lomefloxacin	none	{'e1': {'word': 'moxifloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d231.s6.e0'}, 'e2': {'word': 'lomefloxacin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d231.s6.e1'}, 'sentence_id': 'DDI-MedLine.d231.s6'}	The response of DRUG and DRUGOTHER after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector .
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Moxifloxacin	Lomefloxacin	none	{'e1': {'word': 'Moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e0'}, 'e2': {'word': 'Lomefloxacin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d231.s8.e1'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	DRUG and DRUGOTHER reacts faster with DRUGUNRELATED and DRUGUNRELATED in acidic media whereas with DRUGUNRELATED in basic media and DRUGUNRELATED in neutral media .
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Moxifloxacin	sucralfate	mechanism	{'e1': {'word': 'Moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e0'}, 'e2': {'word': 'sucralfate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d231.s8.e2'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	DRUG and DRUGUNRELATED reacts faster with DRUGOTHER and DRUGUNRELATED in acidic media whereas with DRUGUNRELATED in basic media and DRUGUNRELATED in neutral media .
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Moxifloxacin	gelusil	mechanism	{'e1': {'word': 'Moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e0'}, 'e2': {'word': 'gelusil', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d231.s8.e3'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	DRUG and DRUGUNRELATED reacts faster with DRUGUNRELATED and DRUGOTHER in acidic media whereas with DRUGUNRELATED in basic media and DRUGUNRELATED in neutral media .
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Moxifloxacin	erythromycin	mechanism	{'e1': {'word': 'Moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e0'}, 'e2': {'word': 'erythromycin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d231.s8.e4'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	DRUG and DRUGUNRELATED reacts faster with DRUGUNRELATED and DRUGUNRELATED in acidic media whereas with DRUGOTHER in basic media and DRUGUNRELATED in neutral media .
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Moxifloxacin	multi-minerals	mechanism	{'e1': {'word': 'Moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e0'}, 'e2': {'word': 'multi-minerals', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d231.s8.e5'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	DRUG and DRUGUNRELATED reacts faster with DRUGUNRELATED and DRUGUNRELATED in acidic media whereas with DRUGUNRELATED in basic media and DRUGOTHER in neutral media .
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Lomefloxacin	sucralfate	mechanism	{'e1': {'word': 'Lomefloxacin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d231.s8.e1'}, 'e2': {'word': 'sucralfate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d231.s8.e2'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	DRUGUNRELATED and DRUG reacts faster with DRUGOTHER and DRUGUNRELATED in acidic media whereas with DRUGUNRELATED in basic media and DRUGUNRELATED in neutral media .
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Lomefloxacin	gelusil	mechanism	{'e1': {'word': 'Lomefloxacin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d231.s8.e1'}, 'e2': {'word': 'gelusil', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d231.s8.e3'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	DRUGUNRELATED and DRUG reacts faster with DRUGUNRELATED and DRUGOTHER in acidic media whereas with DRUGUNRELATED in basic media and DRUGUNRELATED in neutral media .
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Lomefloxacin	erythromycin	mechanism	{'e1': {'word': 'Lomefloxacin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d231.s8.e1'}, 'e2': {'word': 'erythromycin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d231.s8.e4'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	DRUGUNRELATED and DRUG reacts faster with DRUGUNRELATED and DRUGUNRELATED in acidic media whereas with DRUGOTHER in basic media and DRUGUNRELATED in neutral media .
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Lomefloxacin	multi-minerals	mechanism	{'e1': {'word': 'Lomefloxacin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d231.s8.e1'}, 'e2': {'word': 'multi-minerals', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d231.s8.e5'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	DRUGUNRELATED and DRUG reacts faster with DRUGUNRELATED and DRUGUNRELATED in acidic media whereas with DRUGUNRELATED in basic media and DRUGOTHER in neutral media .
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	sucralfate	gelusil	none	{'e1': {'word': 'sucralfate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d231.s8.e2'}, 'e2': {'word': 'gelusil', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d231.s8.e3'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	DRUGUNRELATED and DRUGUNRELATED reacts faster with DRUG and DRUGOTHER in acidic media whereas with DRUGUNRELATED in basic media and DRUGUNRELATED in neutral media .
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	sucralfate	erythromycin	none	{'e1': {'word': 'sucralfate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d231.s8.e2'}, 'e2': {'word': 'erythromycin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d231.s8.e4'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	DRUGUNRELATED and DRUGUNRELATED reacts faster with DRUG and DRUGUNRELATED in acidic media whereas with DRUGOTHER in basic media and DRUGUNRELATED in neutral media .
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	sucralfate	multi-minerals	none	{'e1': {'word': 'sucralfate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d231.s8.e2'}, 'e2': {'word': 'multi-minerals', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d231.s8.e5'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	DRUGUNRELATED and DRUGUNRELATED reacts faster with DRUG and DRUGUNRELATED in acidic media whereas with DRUGUNRELATED in basic media and DRUGOTHER in neutral media .
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	gelusil	erythromycin	none	{'e1': {'word': 'gelusil', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d231.s8.e3'}, 'e2': {'word': 'erythromycin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d231.s8.e4'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	DRUGUNRELATED and DRUGUNRELATED reacts faster with DRUGUNRELATED and DRUG in acidic media whereas with DRUGOTHER in basic media and DRUGUNRELATED in neutral media .
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	gelusil	multi-minerals	none	{'e1': {'word': 'gelusil', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d231.s8.e3'}, 'e2': {'word': 'multi-minerals', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d231.s8.e5'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	DRUGUNRELATED and DRUGUNRELATED reacts faster with DRUGUNRELATED and DRUG in acidic media whereas with DRUGUNRELATED in basic media and DRUGOTHER in neutral media .
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	erythromycin	multi-minerals	none	{'e1': {'word': 'erythromycin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d231.s8.e4'}, 'e2': {'word': 'multi-minerals', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d231.s8.e5'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	DRUGUNRELATED and DRUGUNRELATED reacts faster with DRUGUNRELATED and DRUGUNRELATED in acidic media whereas with DRUG in basic media and DRUGOTHER in neutral media .
"Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells.
"	celecoxib	anti-cancer drugs	effect	{'e1': {'word': 'celecoxib', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d217.s0.e0'}, 'e2': {'word': 'anti-cancer drugs', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d217.s0.e1'}, 'sentence_id': 'DDI-MedLine.d217.s0'}	Interaction of DRUG with different DRUGOTHER is antagonistic in breast but not in other cancer cells .
This study investigates the ability of cyclooxygenase-2 inhibitors to sensitize cells from different origins to several chemotherapeutic agents. 	cyclooxygenase-2 inhibitors	chemotherapeutic agents	none	{'e1': {'word': 'cyclooxygenase-2 inhibitors', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d217.s2.e0'}, 'e2': {'word': 'chemotherapeutic agents', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d217.s2.e1'}, 'sentence_id': 'DDI-MedLine.d217.s2'}	This study investigates the ability of DRUG to sensitize cells from different origins to several DRUGOTHER .
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	5-FU	cisplatin	none	{'e1': {'word': '5-FU', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d217.s4.e0'}, 'e2': {'word': 'cisplatin', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d217.s4.e1'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	The sensitivity , cell cycle , apoptosis and DNA damage of five different cancer cell lines ( HeLa , HCT116 , HepG2 , MCF7 and U251 ) to DRUG , DRUGOTHER , DRUGUNRELATED and DRUGUNRELATED DRUGUNRELATED following different incubation schedules were analyzed .
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	5-FU	doxorubicin	none	{'e1': {'word': '5-FU', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d217.s4.e0'}, 'e2': {'word': 'doxorubicin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d217.s4.e2'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	The sensitivity , cell cycle , apoptosis and DNA damage of five different cancer cell lines ( HeLa , HCT116 , HepG2 , MCF7 and U251 ) to DRUG , DRUGUNRELATED , DRUGOTHER and DRUGUNRELATED DRUGUNRELATED following different incubation schedules were analyzed .
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	5-FU	etoposide	none	{'e1': {'word': '5-FU', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d217.s4.e0'}, 'e2': {'word': 'etoposide', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d217.s4.e3'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	The sensitivity , cell cycle , apoptosis and DNA damage of five different cancer cell lines ( HeLa , HCT116 , HepG2 , MCF7 and U251 ) to DRUG , DRUGUNRELATED , DRUGUNRELATED and DRUGOTHER DRUGUNRELATED following different incubation schedules were analyzed .
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	5-FU	celecoxib	none	{'e1': {'word': '5-FU', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d217.s4.e0'}, 'e2': {'word': 'celecoxib', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d217.s4.e4'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	The sensitivity , cell cycle , apoptosis and DNA damage of five different cancer cell lines ( HeLa , HCT116 , HepG2 , MCF7 and U251 ) to DRUG , DRUGUNRELATED , DRUGUNRELATED and DRUGUNRELATED DRUGOTHER following different incubation schedules were analyzed .
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	cisplatin	doxorubicin	none	{'e1': {'word': 'cisplatin', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d217.s4.e1'}, 'e2': {'word': 'doxorubicin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d217.s4.e2'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	The sensitivity , cell cycle , apoptosis and DNA damage of five different cancer cell lines ( HeLa , HCT116 , HepG2 , MCF7 and U251 ) to DRUGUNRELATED , DRUG , DRUGOTHER and DRUGUNRELATED DRUGUNRELATED following different incubation schedules were analyzed .
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	cisplatin	etoposide	none	{'e1': {'word': 'cisplatin', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d217.s4.e1'}, 'e2': {'word': 'etoposide', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d217.s4.e3'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	The sensitivity , cell cycle , apoptosis and DNA damage of five different cancer cell lines ( HeLa , HCT116 , HepG2 , MCF7 and U251 ) to DRUGUNRELATED , DRUG , DRUGUNRELATED and DRUGOTHER DRUGUNRELATED following different incubation schedules were analyzed .
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	cisplatin	celecoxib	none	{'e1': {'word': 'cisplatin', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d217.s4.e1'}, 'e2': {'word': 'celecoxib', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d217.s4.e4'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	The sensitivity , cell cycle , apoptosis and DNA damage of five different cancer cell lines ( HeLa , HCT116 , HepG2 , MCF7 and U251 ) to DRUGUNRELATED , DRUG , DRUGUNRELATED and DRUGUNRELATED DRUGOTHER following different incubation schedules were analyzed .
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	doxorubicin	etoposide	none	{'e1': {'word': 'doxorubicin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d217.s4.e2'}, 'e2': {'word': 'etoposide', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d217.s4.e3'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	The sensitivity , cell cycle , apoptosis and DNA damage of five different cancer cell lines ( HeLa , HCT116 , HepG2 , MCF7 and U251 ) to DRUGUNRELATED , DRUGUNRELATED , DRUG and DRUGOTHER DRUGUNRELATED following different incubation schedules were analyzed .
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	doxorubicin	celecoxib	none	{'e1': {'word': 'doxorubicin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d217.s4.e2'}, 'e2': {'word': 'celecoxib', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d217.s4.e4'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	The sensitivity , cell cycle , apoptosis and DNA damage of five different cancer cell lines ( HeLa , HCT116 , HepG2 , MCF7 and U251 ) to DRUGUNRELATED , DRUGUNRELATED , DRUG and DRUGUNRELATED DRUGOTHER following different incubation schedules were analyzed .
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	etoposide	celecoxib	none	{'e1': {'word': 'etoposide', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d217.s4.e3'}, 'e2': {'word': 'celecoxib', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d217.s4.e4'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	The sensitivity , cell cycle , apoptosis and DNA damage of five different cancer cell lines ( HeLa , HCT116 , HepG2 , MCF7 and U251 ) to DRUGUNRELATED , DRUGUNRELATED , DRUGUNRELATED and DRUG DRUGOTHER following different incubation schedules were analyzed .
We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. 	celecoxib	celecoxib	none	{'e1': {'word': 'celecoxib', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d217.s5.e0'}, 'e2': {'word': 'celecoxib', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d217.s5.e1'}, 'sentence_id': 'DDI-MedLine.d217.s5'}	We found antagonism between DRUG and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between DRUGOTHER and DRUGUNRELATED in all cell lines except for two combinations in HCT116 cells .
We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. 	celecoxib	doxorubicin	none	{'e1': {'word': 'celecoxib', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d217.s5.e0'}, 'e2': {'word': 'doxorubicin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d217.s5.e2'}, 'sentence_id': 'DDI-MedLine.d217.s5'}	We found antagonism between DRUG and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between DRUGUNRELATED and DRUGOTHER in all cell lines except for two combinations in HCT116 cells .
We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. 	celecoxib	doxorubicin	effect	{'e1': {'word': 'celecoxib', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d217.s5.e1'}, 'e2': {'word': 'doxorubicin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d217.s5.e2'}, 'sentence_id': 'DDI-MedLine.d217.s5'}	We found antagonism between DRUGUNRELATED and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between DRUG and DRUGOTHER in all cell lines except for two combinations in HCT116 cells .
These results, if confirmed in-vivo, indicate that celecoxib is not a suitable chemosensitizer for breast cancer or with doxorubicin for other cancers. 	celecoxib	doxorubicin	none	{'e1': {'word': 'celecoxib', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d217.s11.e0'}, 'e2': {'word': 'doxorubicin', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d217.s11.e1'}, 'sentence_id': 'DDI-MedLine.d217.s11'}	These results , if confirmed in - vivo , indicate that DRUG is not a suitable chemosensitizer for breast cancer or with DRUGOTHER for other cancers .
